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RÉSUMÉ 
La production excessive de mucus visqueaux dans les poumons des patients atteints de la 
fibrose kystique (FK) gêne la diffusion des médicaments et entraîne des infections 
bactériennes. En effet, l’infection pulmonaire par Pseudomonas aeruginosa (PA) est la 
principale cause de mortalité. Les travaux effectués dans cette thèse avaient pour but de 
développer des nouvelles formulations de nanoparticules (NP) et de liposomes (LP) chargées 
avec des antibiotiques pour erradiquer le PA chez les patients atteints de KF. Tout d’abord, 
les polymères PEG-g-PLA et PLA-OH ont été synthétisés et caractérisés. Ensuite, l'efficacité 
d'encapsulation (EE) de la tobramycine, du sulfate de colistine et de la lévofloxacine (lévo) a 
été testée dans des NP de PEG-g-PLA et / ou PLA-OH. Les premiers essais d'optimisation ont 
montré que les NP chargées avec la lévo présentaient une augmentation de l’EE. La lévo 
reste alors le médicament de choix. Cependant, la meilleure charge de médicament obtenue 
était de 0,02% m/m. Pour cette raison, nous avons décidé d'évaluer l'encapsulation de la lévo 
dans les LP. En fait, des LP chargés de lévo ont présenté une EE d’environ 8% m/m. De plus, la 
taille et la charge de ces LP étaient appropriées pour la pénétration du vecteur dans le 
mucus. Le test de biofilm n'est pas reproductible, mais le test standard a montré que la 
souche mucoïde de PA était susceptible à la lévo. Ainsi, nous avons comparé les activités des 
LP fraîchement préparées (vides et chargés ) et de la lévo libre sous la forme planctonique de 
PA. Les résultats ont montré que des LP vides ne gênent pas la croissance bactérienne. Pour 
la souche mucoïde (Susceptible à la lévo) les LP chargés et le médicament libre ont présenté 
la même concentration minimale inhibitrice (CMI). Toutefois, les souches non mucoïdes 
(résistant à la lévo) ont présenté une CMI deux fois plus faible que celle pour le médicament 
libre. Finalement, les LP se sont avérés plus appropriés pour encapsuler des médicaments 
hydrophiles que les NP de PEG-g-PLA. En outre, les LP semblent améliorer le traitement 
contre la souche résistante de PA. Toutefois, des études complémentaires doivent être 
effectuées afin d'assurer la capacité des liposomes èa traiter la fibrose kystique. 
Mots-clés : antibiotique , nanoparticules polymèriques, PEG-g-PLA, liposomes, Pseudomonas 
aeruginosa, biofilm, Fibrose Kystique. 
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ABSTRACT 
The increased production of viscoid mucus in the lungs of cystic fibrosis (CF) patients hinders 
the diffusion of therapeutics and favor bacterial infections. Indeed, lung infection by 
Pseudomonas aeruginosa (PA) relates with increased mortality in CF patients. This work is 
aimed at developing new antibiotic loaded nanoparticles and liposomes formulations to 
eradicate PA in CF. Firstly, PEG-g-PLA and PLA-OH polymers were synthesized and 
characterized. Afterwards, the loading efficiency (LE) of tobramycin, colistin sulfate and 
levofloxacin was evaluated in PEG-g-PLA and/or PLA-OH nanoparticles (NP). Early stage of 
optimization showed that levofloxacin NP exhibited increased LE thus this drug was selected 
for further optimization. However, the highest levofloxacin LE accomplished was 0.02% w/w. 
Thus, we decided to evaluate the levofloxacin LE into liposomes (LP). In fact, levofloxacin LP 
exhibited drug loading of 8% w/w with a size and charge suitable for mucus penetration. 
Preliminary evaluation of free tobramycin, colistin sulfate and levofloxacin against PA 
showed that the biofilm test was not reproducible. However, the traditional test in the 
planktonic form of PA showed that the mucoid strain was susceptible to levofloxacin. Thus, 
we evaluated fresh LP (blank and loaded) and free levofloxacin formulations against the 
planktonic form of PA (mucoid and non-mucoid strains). Results showed that blank LP did not 
interfere with the bacterial growth. Loaded LP presented similar minimal inhibitory 
concentration (MIC) for the susceptible mucoid strain and half MIC for the resistant non-
mucoid strain when compared to the free drug. To conclude, LP seemed more appropriate to 
encapsulate hydrophilic drugs than polymeric PEG-g-PLA nanoparticles. Also, levofloxacin 
loaded LP seemed to improve the treatment against resistant strain of PA when compared to 
the free drug. However, further studies need to be performed to conclude whether 
levofloxacin LP are a promising option for the treatment of CF. 
 
Keywords: antibiotics, polymeric nanoparticles, PEG-g-PLA, liposomes, Pseudomonas 
aeruginosa, biofilm, Cystic Fibrosis. 
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Introduction 
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1.1. Cystic Fibrosis  
 
1.1.1  Historical background 
 
Cystic fibrosis (FC) was first pathologically distinguished from celiac disease in 1938. Autopsy 
studies from malnourished children characterized a newborn disease of mucus plugging of 
the glandular ducts named “Cystic Fibrosis of the pancreas”. This disease was characterized 
by pancreatic damage and lack of pancreatic enzymes secretion resulting in nutritional 
failure which was assumed to be related with increased vulnerability to lung infection. At 
this time, the life expectancy was 6 months and death normally occurred as a result of lung 
inflammation. The disease was also designed as “Mucoviscidosis” and later was referred as 
“generalized exocrinopathy” since many exocrine glands were affected. At this time, CF was 
already considered an autosomal recessive disease. Later, better elucidation of the disease 
was possible due to the advents of the sweat electrolyte defect discovered in 1953. They 
found that the sweat of CF patients possessed an increased concentration of salts. 
Afterwards, the development of the standardized sweat test in 1959 allowed the 
identification of mild cases. Thus, the disease was no longer considered only a disorder of 
mucus production (1). In 1983, the chloride transport was identified as the major defect in 
CF accompanied by increased sodium reabsorption. Although CF has been diagnosed since 
1938, it is only in 1989 that the mechanism was discovered, thanks to the discovery of the 
CFTR gene (2). Located in the long arms of chromosome 7, the CFTR gene encodes a protein 
that functions as an anion channel: the phosphorylated-dependent epithelial chloride 
channel (3) (Figure 1).  
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Figure 1. The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene and its 
encoded polypeptide.The human CFTR gene (top) is located on the long arm of chromosome 7 and consists of 27 exon regions 
that encode the 1,480 amino acid CFTR proteins (middle). The mature protein after proper folding, glycosylation, and insertion into the cell 
membrane is shown at the bottom. The CFTR protein is a member of the ATP-binding cassette (ABC) family of transporters. It contains two 
nucleotide-binding domains that bind and hydrolyze ATP, two dual sets of membrane-spanning segments that form the channel, and a 
central regulatory (R) domain. The R domain, unique to CFTR, is highly charged with numerous phosphorylation sites for protein kinases A or 
C.(Reprinted by permission from Reference 490).  
Taken from reference (3). 
 
According to its primary structure, the CFTR channel is classified as a family member of the 
transport proteins class called ATP-biding cassette (ABC) transporter. These transporters 
utilize the energy of ATP hydrolysis to actively transport molecules across cell membranes. 
The CFTR channel is located in the apical membrane of epithelial tissues and is responsible 
for the regulation of chloride flow across epithelia cells. Thus, it has a crucial role in the 
control of transepithelial salt transport, fluid flow and ion concentration (4).  
To date, more than 1900 mutations in the CFTR gene have been reported (5). In Canada, the 
most prevalent mutation (91.5%) is a deletion of a three-base pair which results in the loss of 
a phenylalanine residue at position 508 of the CFTR protein sequence (F508del) (6). 
Depending on the kind of mutation, the ion channel can work partially or completely fail 
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characterizing different symptoms and severity of the disease. However, the development of 
symptoms cannot be predicted based solely on DNA analysis, since some symptoms are also 
determined by phenotypic aspects, such as in the case of the pulmonary disease. However, 
the prediction of development of pancreatic disease is more genetically based. 
 
1.1.2  Symptoms 
As a variety of organs are lined by epithelial cells such as sweet ducts, airways, pancreatic 
ducts, biliary tree, intestines and vas deferens, cystic fibrosis leads to be a multi-systemic 
disease. The manifestations includes elevated sweat chloride concentration, lung disease, 
intestinal obstruction, pancreatic insufficiency with diabetes and impaired absorption, the 
latter due to inadequate secretion of digestive enzymes, biliary cirrhosis and congenital 
collateral absence of the vas deferens, often in combination (1, 7) . 
Despite being a multi-systemic disease, approximately fifty percent of all patients are 
harmed with bacterial infection in the lungs (6). In addition, according to the Canadian Cystic 
Fibrosis Registry (2011), the main cause of death is pulmonary-related (6). Thus, given the 
impact of the pulmonary disease in the survival of CF patients, there is an unmet need for 
the development of new treatments for the chronic lung infections.  
 
 
1.2. Lung Disease Phase in Cystic Fibrosis 
 
1.2.1. Pulmonary dysfunctions due to CFTR mutations 
The airways epithelium is formed by ciliated epithelial cells responsible to reabsorb 
electrolyte and goblet cells (glandular simple columnar epithelial cells). The latter are 
responsible for secreting mucins (the major component of mucus) and to generate the 
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airway surface liquid (ASL). As shown in figure 2- scheme a, the normal airways are covered 
by the periciliary liquid layer which is composed of the cilium and a mucus layer. The 
function of the periciliary layer to provide a low-viscosity solution for ciliary beat which 
allows the mucus transport, therefore its volume and ion concentration are tightly 
regulated. The mucus layer is formed by high molecular-weight mucins whose properties are 
altered by electrolyte concentration, water content and pH. Ultimately, the mucin structure 
consists of numerous diversified carbohydrate side chains which are suitable for binding a 
wide variety of particles, as a mechanism to clear the airway through the mucus transport. 
Most importantly, it is widely accepted that the sensible adjustment in the electrolyte 
transport by the airway epithelium and submucosal glands controls the volume and 
composition of the ASL. Thus, as shown in the figure 2- schemes b and c, loss or dysfunction 
of CFTR leads to failure or decrease in the chloride secretion. However, as the sodium 
absorption still takes place, it leads to chloride paracellular absorption and water influx 
generating dehydration of ASL and build up of high viscous mucus. As a consequence, the 
cilium beat is impeded and the mucus transport does not take place. All these impairments 
together favors infection by bacteria and limits the pulmonary host defense due to loss of 
mucociliary clearance of bacteria(8) (Figure 2- schemes d and e). 
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Figure 2: Normal mucus clearance mechanisms and failure to adequately hydrate CF airway 
surfaces. (a) Normal airways coordinate rates of Na+ absorption and Cl- secretion to hydrate airway surfaces. (b) In CF, the absence of 
CFTR protein/function in the apical membrane leads to unregulated Na
+
(Cl
-
 follows assively via paracellular path—not shown) and water 
absorption. The pathophysiologic sequence that follows CF dehydration is depicted in diagrams c–e. (c) Mucin secretion into adherent 
mucus plaque is depicted as emanating from goblet cells/glands. (d–e) Bacteria within mucus plaques/plugs are depicted as acrocolonies. 
Bars depict O2 tension in ASL (red, oxygenated; blue, hypoxic). NL=normal lung; CF= Lung of patients with CF.  
Taken from reference (8). 
 
1.2.2. Pulmonary Infection by Pseudomonas aeruginosa 
Numerous microorganisms have been isolated from the lungs of CF patients such as 
Aspergillus fumigatus species, Haemophilus influenzae, Stenotrophomonas maltophilia(9), 
Burkholderia cepacia complex, Alcaligenes species, atypical mycobacteria and methicilin-
resistent Staphylococcus aureous (MRSA) (6) (figure 3). In addition, viral infections also play 
an important role in the development of the CF disorder(10). However, the most prevalent 
bacteria are Pseudomonas aeruginosa and Staphylococcus aureus depending on age (6). 
Pseudomonas aeruginosa is a gram-negative bacillus, non-encapsulated and non-spore 
formers, which infects predominantly the lower respiratory tract. 
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Figure 3: Prevalence of respiratory infections, 2007-2011. Taken from reference (6). 
 
Studies have shown that early infection in the airways of CF patients is most frequently 
caused by S. aureus and H. influenzae. In the other hand, the most prevalent pathogen 
isolated in adults is Pseudomonas aeruginosa (Figure 4).  
 
Figure 4: Age-specific prevalence of respiratory infection in CF patients, 2011. Taken from 
reference (6). 
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Indeed, pulmonary infection by Pseudomonas aeruginosa is closely related to an increase in 
mortality and morbidity of CF patients (6, 11) . However, it should be mentioned that other 
pathogens, such as Burkholderia ssp. (12)., Achromobacter ssp. (13) and Stenotrophomonas 
maltophilia (9) also contribute to morbidity and / or mortality .  
Thus, these data support the importance of the development of new therapeutic strategies 
in order to prevent pulmonary exacerbations caused by these microorganisms. Pulmonary 
exacerbations are defined as the increased manifestation of respiratory symptoms such as 
cough and sputum production, often accompanied by systemic symptoms such as anorexia 
and malaise (14) . The occurrence of these symptoms defines the necessity of treatment 
adjustment in order to preserve pulmonary capacity and assure increased lifespan. 
 
1.2.3. Biofilm formation 
Numerous researchers have studied the underlying reasons why the immune system of CF 
patients is not effective to eliminate the early lung colonization by P. aeruginosa. However, 
how CFTR mutations enhance susceptibility to pulmonary infection and how this 
vulnerability could be prevented still remains unclear.  
Cystic Fibrosis is correlated with increased proinfammatory signals; however this does not 
result in efficient clearance of bacteria. In fact, the failure to clear infection causes cyclic 
neutrophil influx which releases oxidants and proteases (15). This environment is 
characterized by low level of oxygen that triggers the change in the morphology of 
Pseudomonas aeruginosa from planktonic (mobile) to biofilm form (figure 2 – diagrams d-e). 
In addition, the bacteria which were strictly aerobic develop the ability to undergo anaerobic 
respiration (16). Mutations enable the bacteria to produce an extracellular polysaccharide 
(EPS) matrix composed mainly of alginate, the biofilm (figure 5).  
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Figure 5: A model of the stages of bacterial biofilm development. At stage 1, the bacterial cells attach 
reversibly to the surface. Then, at stage 2, the cells attach irreversibly, a step mediated mainly by exopolymeric substances, and the cells 
lose their flagella-driven motility. At the next stage (3), the first maturation phase is reached, as indicated by early development of biofilm 
architecture. The second maturation phase is reached at stage 4 with fully mature biofilms, as indicated by the complex biofilm 
architecture. At the dispersion stage (5), single motile cells (dark cells on the figure) disperse from the microcolonies. Adapted from 
(17).Taken from reference (18). 
In the biofilm form, the bacteria lose their flagellum which is recognized by the 
immunological system. In fact, P. aeruginosa isolated from chronically infected CF patients 
also have mutations enabling mucus production (mucoid strains) rendering them highly 
resistance to antibiotic and neutrophil-mediated killings. After maturation, these colonies of 
bacteria encased in the alginate matrix can return to the planktonic form (mobile) and 
disperse to colonize new niches (17). The genetic processes related to biofilm formation and 
dispersion has been extensively described in the literature (19).  
 
1.2.4. Treatments 
 
1.2.4.1. Treatment of the lung disease 
The main goal of the treatment of the lung disease is to successfully eradicate 
microorganisms by antibiotic therapy. However, the establishment of chronic lung 
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inflammation is inevitable. Thus, other medications for chronic use are indicated to treat the 
symptoms due to pulmonary inflammation, as listed in table I (20). 
Table I: Chronic medications for maintenance of lung health. 
Class of drugs Examples Objective 
Mucolytics Dornase alpha (inhalation) 
Increase mucus fluidity, hence aiding mucus clearance. 
Recombinant human DNase degrades the residual 
DNA caused by neutrophils infiltration. 
Osmotic agents 
Hypertonic saline 
(inhalation) 
Manitol (inhalation) 
Reestablish the hydration condition of the ASL and 
improve the mucus transport rate. Osmotic agents 
draw water from the interstitium into the ASL which 
allows increased ciliary beat and cough clearance.  
β2-adrenergic receptor 
agonists  
Salbutamol, salmeterol 
(inhalation) 
Treat reactive airway disease. 
 
1.2.4.2. Treatment of lung infection caused by Pseudomonas aeruginosa 
Antibiotic therapy against P. aeruginosa aims at increasing the life expectancy of patients by 
preventing pulmonary exacerbations which can result in irreversible loss of pulmonary 
capacity. Thus, aggressive and early antibiotic treatment of P. aeruginosa is associated with 
increased life expectancy (21, 22), since in most cases resistant bacterial cells selected over 
time in chronic infection cannot be eradicated. Although the pulmonary route is always 
favored due to decreased level of side effects and increased concentrations, the 
concomitant administration of systemic drugs (orally or intravenously) may also be 
indicated, depending on the severity of the infection. Indeed clinical practice is the main 
resource to guide physicians to the appropriate choice of the antibiotic therapy. However, 
the antibiotic arsenal is finite and limited to combat P. aeruginosa which exhibits a strong 
capacity to mutate into resistant forms and is hyper adapted to the lungs of CF patients. In 
addition, the slow development of new classes of antimicrobials suggests that it is 
worthwhile to invest in the development of new formulation for current drugs. In fact, 
pharmacotechnical research allows changes in the drug’s pharmacokinetic properties which 
can be adapted to better target P. aeruginosas in the lungs. These innovative strategies 
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(presented in section 1.2.4.4), represent an important alternative to improve the bacterial 
eradication in cystic fibrosis, which is directly related to the longevity of CF patients. 
 
1.2.4.3. Chronic Pseudomonas aeruginosa pulmonary infection 
The use of aminoglycosides is recommended for the chronic suppressive therapy of P. 
aeruginosa in an alternating 28-day on/off regimen. Two different formulations are available 
including solution for inhalation and intravenous preparation also used for inhalation, as 
explained in table II.  
Table II: Aerosolized aminoglycosides for the chronic suppressive therapy of P. aeruginosas. 
Active (Trade Name) Dose 
TIS (tobramycin inhalation solution) – TOBI®  300 mg/ twice a day (23). 
NIT (nebulized intravenous tobramycin) - 
Nebcin ® 
Children: 70-120 mg twice or three times a day. Adults: 80-160 
mg twice or three times a day (23). 
NIT - (Sabex) 80-160 mg twice daily (23). 
Amikacin® (Bristol) – intravenous formulation 
used by nebulization. 
250 mg twice daily for children and 250-500 mg twice daily for 
adults (24). 
 
Although there are no thorough studies to demonstrate the clinical efficacy of colistimethate 
sodium, this drug can also be prescribed to treat multi-resistant strains (24, 25). Thus, 
colistin (Coly-Mycin® M Parenteral - ERFA Canada Inc.) is indicated as another option and is 
supplied as an aerosol preparation (powder for reconstitution to 150 mg/2 mL). Colistin is 
also available as an intravenous formulation for nebulization (Colobreathe ®). The aerosol 
dosage recommended for Colobreathe ® is 25-150 mg (intravenous dry powder) twice or 
three times daily (24). 
Beta-lactams are also available to fight pseudomonal infections in CF patients. Aztreonam, 
carbapenems, cephalosporins (ceftazidime and cefapime) and penicilins are indicated for 
intravenous administration (26-28). 
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1.2.4.4. Recently approved therapies  
Given the advantages of the pulmonary administration over systemic routes for the 
treatment of cystic fibrosis, recent research efforts have focused in the development of new 
antibiotic formulations such as powder for nebulization or powder for inhalation, as listed in 
table III. 
Table III: Recently approved aerosolized antibiotics for the treatment of cystic fibrosis. 
Drug Formulation Comments 
CMS
a
 (Colomycin®-Forest 
and Promixin®-Profile 
Pharma) 
Intravenous formulation used 
for nebulization. 
Composed by colistimethate sodium (CMS). 
Administered by Jet nebulizer. Administration 
time is 15 minutes. Formulation must be 
refrigerated (29) 
CMS
a
 (Colobreathe®)  Dry powder for inhalation (DPI). 
Composed by colistimethate sodium (CMS). 
Administrated with the Turbospin inhalation 
device. Administration time is approximately 
1minute. Storage at room temperature (30).  
Aztreonam lysine (AZLI, 
Cayston®, Gilead Sciences)  
Powder for nebulization 
(aerosol).  
Administrated with an electronic vibrating 
mesh nebulizer (Altera®). Administration time 
is 3 minutes. Formulation must be 
refrigerated. The CEDAC recommends the use 
of aztreonam inhalation solution for the 
treatment of chronic P. aeruginosa infection 
in patients with moderate to severe CF and 
deteriorating clinical condition despite 
treatment with inhaled tobramycin (31, 32).  
Tobramycin (TOB 
Podhaler®- Novartis)
c 
 
DPI administrated with the 
Podhler (T-326) inhaler. 
Tobramycin Inhalation Powder (TIP). 
Administration time is under 6 minutes. 
Storage at room temperature (33). 
CEDAC: Canadian Expert Drug Advisory Committee: CF: Cystic Fibrosis. 
aApproved in the European Union (EU). 
bApproved for the treatment of CF patients infected with P aeruginosa in Australia and USA, and conditionally approved in Canada and EU. 
The Canadian Expert Drug Advisory Committee (CEDAC) recommends the use of aztreonam inhalation solution (28-day cycles) for the 
treatment of chronic P. aeruginosa infection in patients with moderate to severe cystic fibrosis and deteriorating clinical condition despite 
treatment with inhaled tobramycin. 
cApproved in European Union, Canada, Switzerland and other countries. 
 
It has to be mentioned that the solution for inhalation requires the use of a nebulizer and 
compressor combination that can be noisy and difficult to transport. Additionally, nebulizers 
require long time for administration which may include the cleaning step of the equipments. 
Thus, the development of powder for inhalation must be encouraged since the advantage to 
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have rapid drug delivery with a portable inhaler includes potentially improving patient 
adherence. 
All formulations discussed in table III are composed of free drugs. Indeed, they are 
aerosolized formulations which bring therapeutic improvements the treatment of CF since 
they enable the pulmonary administration of antibiotics. However, additional benefits would 
be achieved with the application of an aerosolized sustained delivery formulation (drug 
encapsulated into nanocarriers), as will be discussed afterwards. 
 
1.2.5. Causes for treatment failure 
 
1.2.5.1. Patient compliance 
The new advances in the treatment of cystic fibrosis and aggressive management of lung 
disease have resulted in great improvements of the patient’s length and quality of life. 
However, as the number of treatments expands, the medical regimens become increasingly 
tiresome and time-consuming (34). Therefore, treatment burden for patients with cystic 
fibrosis is extremely high, and includes a range of inhaled and systemic medications, 
physiotherapy and exercises, often taking more than 2 hours a day (35). 
Non adherence to treatment may cause accelerated disease and increased number of 
hospital admissions. The overall rate of treatment adherence in children with CF was found 
to be below 50% (36). 
The most important reasons for patient non adherence to treatment include time 
management difficulties, oppositional behavior from children, poor taste when using 
breathing nebulizer for a long period, forgetting to administer the drug and embarrassment 
to take a lot of drugs or receive physiotherapy at school (37). 
Therefore, decreasing the frequency of drug administration, providing safe drug association 
in the same formulation, offering easy and fast administration (important factors in the case 
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of drugs for lung administration) and developing formulations with tolerable taste may be 
promising goals to increase patient adherence and efficacy of antibiotic treatment. For 
instance, sustained drug release can be achieved by encapsulation of drug in a 
biodegradable carrier thus resulting in decreased frequency of drug administration. Such 
goal has been achieved by the liposomal formulation Amikacin® which is now in phase IV of 
clinical trials (38). 
 
1.2.5.2. Pseudomonas aeruginosa resistance to antibiotics 
In spite of aggressive antibiotic therapy, Pseudomonas aeruginosa has demonstrated the 
ability to evade the mechanism of action of antibiotics. Some adaptive mechanisms of 
defense against antibacterial drugs can be listed (table IV) such as changes in the bacterium 
expression of proteins which are target for drugs, lack of membrane porins which are 
important for antibiotic diffusion and expression of drug efflux mechanisms (39, 40). These 
mutations can partially explain their ability to survive and persist for years in the CF patient’s 
lungs. 
Thus, as different classes of antibiotics show diverse modes of action, the rate and 
mechanisms of resistance vary according to the antimicrobial class as can be seen in the 
table IV. 
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Table IV: Main mechanisms of resistance of P. aeruginosa to certain classes of antibiotics.  
Antibiotic Class Examples  Mechanism of action Resistance mechanism 
Fluoroquinolones 
Levofloxacin, 
ciprofloxacin 
Inhibition of DNA synthesis by 
inactivation of topoisomerases II 
and IV (enzymes essential for DNA 
replication). 
Expression of drug efflux 
pumps. Mutations in the 
topoisomerases II and IV (39). 
Aminoglycosides 
Tobramycin, 
gentamicin, 
amikacin. 
Inhibition of protein synthesis by 
antibiotic binding to bacterial 
ribosomes and inhibition of 
ribosomal enzymes. 
Expression of drug efflux 
pumps. Reduction in the 
active transport through the 
membrane. Modifying 
enzymes. 
Beta-lactams 
Imipenem, 
Meropenem, 
aztreonam, 
ceftazidime, 
cefapime. 
Interference with cell wall 
synthesis. 
Production of β-lactamase 
enzymes that inactivate the 
drug. Multi-drug efflux (40) . 
Polymyxins Colistin 
Disrupt the bacterial cell wall 
through osmotic rupture. 
Mutation in the lipid A 
reducing binding of 
polymyxins to 
lipopolysaccharide (h) (41). 
 
Polymyxins had already been considered an alternative for the treatment of multi-resistant 
strains of P. aeruginosa (42). Their bactericidal activity consists of cell membrane disruption 
leading to leakage of cell contents and bacterial death. This is achieved at least in part by 
binding to lipopolysaccharide (LPS), a major component of the Gram-negative cell surface, 
through interactions with phosphates and fatty acids of lipopolysaccharides core and lipid A 
moieties. However, spontaneous polymyxin-resistant mutants of Pseudomonas aeruginosa 
have already been isolated (41). Indeed, lipid A of these mutants contained aminoarabinose 
which reduces binding of polymyxins to LPS, whereby resistance arises (43). 
The increase in bacterial resistance to antibiotics is also related to the route of 
administration. Thus, in the case of cystic fibrosis, the pulmonary route is preferred since it 
allows increased local concentration of antibiotics and longer contact time with the 
pathogen. Moreover, the local mechanism of action provided by pulmonary delivery 
decreases the occurrence of side-effects and the possible occurrence of sub-inhibitory drug 
levels, as can occur in other routes (oral, intravenous) which favors drug resistance (44). In 
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addition, the extended antibiotic release achieved with a nanocarrier would in theory also 
help to maintain the therapeutic concentration of drug in the lungs.  
In addition, a previous study done by our group (45) showed an increased antifungal effect 
of itraconazole, voriconazole and amphotericin B loaded PEG-g-PLA nanoparticles compared 
with the free drug against  resistant strains of Candida ssp and Aspergillus fumigates (these 
strains presented over expression of efflux pumps). These studies showed that PEG-g-PLA 
nanoparticles with small hydrodynamic diameter (˂200 nm) can be internalized in these 
yeast strains and might block the efflux pumps thereby overcoming fungal resistance to 
these drugs. 
 
1.2.5.3. Antibiotic diffusion in the mucus 
The mucus structure can interact with drugs hindering its diffusion through the mucus and 
the targeting of embedded bacteria. Various studies showed that positively charged, low-
molecular weight drugs such as amikacin, tobramycin, gentamicin and some β-lactams 
antibiotics bind to negatively charged components in the mucus (46). Therefore, bacteria are 
exposed to sub-inhibitory level of antibiotics which may induce bacterial resistance and 
biofilm formation (44, 47). 
 
1.2.5.4. Biofilm formation 
The implications of biofilm formation in the resistance to cystic fibrosis treatments have 
been extensively reported. Firstly, the alginate envelope (biofilm matrix) serves as a direct 
barrier against phagocytic cells and effective opsonisation (22). Moreover, alginate has 
immunomodulatory properties stimulating the release of inflammatory cytokines which 
increases lung inflammation and subsequent destruction. Intensive inflammation favors the 
development of hypoxic areas in the lungs that can trigger biofilm formation. The 
polysaccharide matrix can also contribute to antibiotic resistance, since some antibiotics 
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cannot penetrate its structure and sub-inhibitory level of antibiotic can result and bacterial 
selection and resistance (48). Likewise, within the biofilm some cells are dormant escaping 
the mechanism of action of some antibiotics, e.g. penicillins (49). Moreover, the oxidative 
stress inside the biofilm structure results in numerous genetic mutations that are transferred 
horizontally between the cells and confers resistance to antibiotics (50) (51). The main 
mechanisms of antibiotic resistance in biofilms are described in figure 6. 
 
Figure 6: Four hypothesized biofilm resistance mechanisms. 1) The antibiotic (squares) penetrates slowly or 
incompletely; 2) A concentration gradient of a metabolic substrate or product leads to zones of slow or non-growing bacteria (shaded 
cells); 3) An adaptive stress response is expressed by some of the cells (marked cells); 4) A small fraction of the cells differentiate into a 
highly protected persister state (dark cells).Taken from reference (52)  
 
 
1.3. Nanotechnology for pulmonary drug delivery 
 
1.3.1. Nanocarriers for drug delivery in the lungs  
As discussed before, controlled-release formulations are important tools for drug delivery in 
the lungs since they may increase and sustain local drug concentrations which contribute to 
decrease dose frequency and systemic toxicity and result in better patient compliance and 
augmented treatment efficiency. 
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A number of nanocarriers have been developed for drug release in the lungs; therefore we 
have selected the most well-known classes and described their main characteristics in table 
V. 
Table V: Properties of the main nanocarriers produced for drug delivery to the lungs 
Carrier properties Liposomes 
Polymeric 
Nanoparticles 
Solid-Lipid 
nanoparticles 
References 
Incorporate both hydrophilic and 
hydrophobic drugs. 
+ ± + 
(53, 54) 
Release drug over time. ± + ± (53, 55) 
Reduce dose frequency. + + + (22, 55-58) 
Maintain their integrity after nebulization. ± + + (54, 55, 59-64) 
Penetrate biofilms. + + - (38, 58, 64-66) 
Penetrate the mucus. - + - 
(38, 63, 67, 
68) 
Stability during storage. - + + 
(53, 54, 63, 
64) 
 
The structural configuration of nanocarriers described in table V is displayed in figure 7. 
 
 
Figure 7: Schematic illustration of four nanoparticle platforms for antimicrobial drug 
delivery: (a) liposome, (b) polymeric nanoparticle, (c) solid lipid nanoparticle, and (d) dendrimer. Black circles represent hydrophobic 
drugs; black squares represent hydrophilic drugs; and black triangles represent either hydrophobic or hydrophilic drugs. Taken from 
reference (53) 
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Liposomes are formed by phospholipid dispersion in water solution that after saturation can 
form micelles able to entrap the drug added to this system. Liposomes are also the most 
investigated system for antibiotic controlled pulmonary delivery, since they may be prepared 
with phospholipids endogenous to the lungs. In addition, their lipid bilayer structure mimics 
the cell membrane and can fuse with infectious microbes to deliver high drug cargos into the 
cytoplasm, saturating their drug efflux pumps, therefore overcoming bacterial resistance 
(69, 70). Moreover, Meers et al have suggested that amikacin-loaded liposomes can also 
penetrate biofilms and infected mucus (38). Although studies have showed that liposomes 
positively charged can penetrate biofilms, positive charge appears to lead to more surface 
adsorption of liposomes at the expense of further penetration. In this respect, Meers et al 
hypothesized that the neutral or zwitterionic lipids used to prepare the amikacin-bearing 
liposomes in their study preclude strong ionic interactions and may help to enhance the 
penetration. Indeed, in this same study, inhaled liposomal amikacin formulation exhibited 
slow sustained released in normal rat lungs and was more efficacious than inhaled free 
amikacin in lungs infected by P. aeruginosas (38). However, liposomes are unstable during 
storage in the liquid and fragile carriers that can be physically destroyed in the nebulization 
process. Moreover, adjusting the drug release profile is a challenge if compared with other 
carriers such as nanoparticles. For instance, tobramycin liposome formulation showed 
increased both drug retention in the lung and antimicrobial activity compared with classical 
formulation. However, long-term efficacy could not be demonstrated by this formulation 
(22).  
Dendrimers are defined as highly ordered and regularly branched globular macromolecules 
synthesized by stepwise iterative approaches. The structure of dendrimers consists of a core, 
layers of branched repeat units emerging from the core, and functional end groups on the 
outer layer of repeat units. Thus, hydrophobic drugs can be loaded inside the cavity core and 
the hydrophilic ones can be loaded in the outer layer through covalent conjugation or 
electrostatic interaction. Although some dendrimers exhibited sustained pulmonary drug 
release and antimicrobial activity itself (53, 56, 64), their activity was far from those of 
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commercialized drugs. In addition their synthesis and purification are time consuming, 
expensive and cumbersome, facts that justify the choice of other nanocarriers.  
Solid lipid nanoparticles are carriers formed by solid lipids such as triglycerides, partial 
glycerides, fatty acids, steroids and waxes and they are able to encapsulate hydrophobic or 
hydrophilic drugs (66). However, they have not yet been fully exploited for pulmonary lung 
delivery. In addition, they can exhibit some drawbacks such as low drug loading and 
unpredictable drug release (58). 
Conversely, polymeric nanoparticles (NP) are easier to formulate in order to reach 
pulmonary sustained release and its use for antimicrobial drug delivery has been extensively 
investigated, since this carriers offer several advantages. For instance, polymeric NP exhibit 
structural stability in biological fluids and under harsh and various conditions for formulation 
(such as spray drying, nebulization) and storage. In addition, by manipulating the 
formulation composition such as polymer chain lengths and concentration, surfactants and 
organic solvents, it is possible to tune polymeric NP properties such as size, charge, drug 
loading and drug release profiles. Furthermore, polymeric NP offer the possibility for 
insertion of chemical groups on its surface to improve mucus penetration and bacterial 
targeting, as will be discussed later.  
 
1.3.2. Polymeric nanoparticles 
A number of synthetic and natural polymers have been used for the synthesis of 
nanoparticles. However, synthetic polymers can be engineered to reach increased sustained 
release as compared with natural polymers such as albumin, gelatin, alginate, collagen, 
cyclodextrins and chitosan (71). Likewise, examples of synthetic polymers used for 
pulmonary applications include poly(lactic acid) (PLA), poly(glycolic acid)(PGA), poly(lactide-
co-glycolide) (PLGA) and poly(ε-carprolactone) (PCL) (72). In addition, these polymers are 
considered non-toxic since they undergo hydrolysis upon implantation into the body, 
degrading into biologically compatible moieties (lactic acid and glycolic acid) which are 
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cleared from the body by the citric acid cycle. Therefore, degradation products are formed 
slowly assuring sustained release and do not affect normal cell function. Indeed, the 
polyesters PLA and PLGA are the most extensively investigated polymers for drug delivery 
(64). They have an hydrophobic core, therefore grafting of hydrophilic motifs such as 
poly(ethylene glycol) (PEG) on both polymer backbone have been studied (73, 74). The 
purposes for the PEG copolymerization are: 1) to facilitate the encapsulation of hydrophilic 
drugs, 2) to increase the resident time in the body, since hydrophobic particles are readily 
cleared by the mononuclear phagocytic system (MPS); 3) to modulate mucus adhesiveness 
in order to achieve mucus penetrating particles (64). 
 
1.3.3. Engineered polymeric nanoparticles for drug delivery in the lungs  
 
1.3.3.1. Mucus penetration particles 
Although the proposal to develop an aerosolized sustained antibiotic release formulation for 
lung administration has the goal of achieving higher antibiotic levels in the lungs, the 
minimal inhibitory concentration (MIC) cannot be attained if the carrier does not diffuse in 
the mucus to target the bacteria. In fact, the build-up mucus acts as a physical, chemical and 
biological barrier to drug penetration, which also contributes to bacterial resistance to 
antibiotics. The mucus is composed mainly by mucins, but also contains DNA, lipids, ions, 
proteins, cells, cellular debris, and water (75). However, dysfunctions in the CFTR alter the 
mucus composition and generate increased viscosity which impairs the diffusion of drugs 
and carriers. Indeed, up to date no gene vector has been shown to penetrate the mucus in 
order to reach the epithelial cells, fact which explains the failure of clinical trials of gene 
therapy for cystic fibrosis (76). Therefore, our goal is to produce mucus inert polymeric 
nanoparticles as an antibiotic carrier able to penetrate the mucus.  
Studies have elucidated the interaction between mucus structure and nanoparticle surface 
coating, in order to decrease NP retention in the mucus, therefore improving nanoparticle 
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diffusion (77).  In addition to hydrophilic sites with negative charges imparted by the 
presence of carboxyl or sulfate groups on the mucin proteoglycans, the mucus also exhibit 
hydrophobic regions along mucin strands, stabilized by multiple internal disulfide bonds. 
These findings explain why the diffusion of both hydrophobic and cationic drugs such as 
tobramycin can be hindered in the mucus (78). However, the mucus is not impenetrable, as 
some viruses such as the human papilloma virus (HPV) can traverse it. In fact, a closer study 
of the HPV structure revealed that they are densely coated with both positively and 
negatively charged groups, leading to a densely charged yet net neutral surface. Based on 
these findings, Hanes and co-workers (67) rationalized that mucus penetrating particles 
must possess a high density on the hydrophilic surface able to minimize hydrophobic 
entrapment of mucus and be small enough to preclude significant steric inhibition by the 
dense fiber mesh, since the mucus structure contains multiple pores. Finally, the PEG 
properties such as being strongly hydrophilic and having a neutral charge make it an 
appropriate nanoparticle coating. However, as studies have also evidenced 
mucoadhesiveness properties of PEG, the rationale was to use a PEG molecule with 
controlled molecular weight. Thus, Hanes et al (67) hypothesized that the PEG molecular 
weight must be low enough to prevent adhesion via polymer interpenetration in the mucus 
(hydroplilic interactions). In addition, PEG density must be sufficient to effectively shield the 
hydrophobic core common to many biodegradable polymers resulting in decreased 
hydrophobic interactions between polymeric nanocarriers and mucus (67) (figure 8). 
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Figure 8: Summary schematic illustrating the fate of mucus-penetrating particles (MPP) and 
conventional mucoadhesive particles (CP) administered to a mucosal surface. MPP readily penetrate 
the luminal mucus layer (LML) and enter the underlying adherent mucus layer (AML). In contrast, CP are largely immobilized in the LML. 
Because MPP can enter the AML and thus are in closer proximity to the cells, cells will be exposed to a greater dose of drug released from 
MPP compared to drug released from CP. As the LML layer is cleared, CP are removed along with the LML whereas MPP in the AML are 
retained, leading to prolonged residence time for MPP at the mucosal surface. In the respiratory airways, CP are mostly immobilized in the 
luminal stirred mucus gel layer, whereas MPP penetrate the mucus gel and enter the underlying periciliary layer. Upon mucociliary 
clearance, a significant fraction of MPP remains in the periciliary layer, resulting in prolonged retention. Taken from reference 
(67). 
 
1.3.3.2. Nanoparticles size and charge 
Therefore, in order to prove the MPP theory, the nanoparticle diffusion in the mucus was 
evaluated by Hanes et al (77) as a function of PEG coating and nanoparticle size. Polystyrene 
particles as large as 200 nm in diameter that were densely coated with low molecular weight 
(2 KDa) polyethylene glycol (PEG) moved through undiluted CF sputum with average speeds 
up to 90-fold faster than similarly-sized uncoated polystyrene particles. Conversely, the 
transport of both coated and uncoated 500 nm particles was strongly hindered (77). These 
nanoparticles exhibited almost neutral surface (zeta potential higher than -10 mV) 
demonstrating that size (≤ 200 nm) and superficial charge (neutral) may also influence in the 
transport of nanoparticles in the mucus. Finally, this experiment proved that nanoparticles 
 
  
24 
 
with correct size, PEG coating and charge may overcome the mucus barrier for the transport 
of nanocarriers. 
 
1.3.4. PEG-g-PLA nanoparticles as a model vector for pulmonary administration 
The synthesis and characterization of PEG-g-PLA polymer have been previously proposed by 
our group of research (74). Briefly, PEG is grafted in the PLA backbone to form an 
amphiphilic polymer. When the outer phase in the emulsification process for nanoparticle 
production is water, this polymer can form nanospheres which are comprised by a 
hydrophobic core mainly composed of PLA and a hydrophilic surface composed of PEG 
coating (figure 9). In polymeric nanocapsules, a polymeric membrane forms a shell with an 
inner space loaded with the drug which are solubilized in aqueous or oily solvents. In 
contrast, nanospheres are solid nanoparticles with the drug homogeneously distributed in 
the polymeric matrices of variable porosity, as expected with PEG-g-PLA nanoparticles (79). 
 
Figure 9: Scheme to represent the structure of PEG-g-PLA nanoparticles. Taken from 
reference (79). 
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The copolymer of PEG and PLA is amphiphilic (have an hydrophobic and an hydrophilic 
portion in the same polymer unit), fact which favors the encapsulation of hydrophilic and 
hydrophobic drugs (54). Hammady and co-workers have already reached the co-
encapsulation of paclitaxel (a hydrophobic drug with a Log P value of 3.96 and water 
solubility of less than 0.01 mg/mL) (80) and endotelin (a hydrophilic drug with solubility of 1 
mg/mL) for the anti-angiogenic treatment of diseases related with an angiogenic component 
(e.g. solid tumors, arthritis, psoriasis, diabetic retinopathy and atherosclerosis) (81). The 
majority of the antibiotics available for the CF treatment are hydrophilic; therefore, we 
believe that PEG-g-PLA might be an appropriate polymer to produce a pulmonary carrier for 
the CF treatment. 
The antimicrobial activity of PEG-g-PLA nanoparticles formulations have also been 
investigated, as compared with the free drug. Two different copolymers of PLA and PEG 
were studied by Essa et al; branched PEGylated polymer in which PEG was grafted on PLA 
back bone (PEG-g-PLA) and multiblock copolymer of PLA and PEG, (PLA–PEG–PLA) (57). In 
addition, PLA nanoparticles were also analyzed. Itraconazole (ITZ) loaded nanoparticles were 
produced with the cited polymers and their in vitro antifungal activity was evaluated against 
both Candida and Aspergillus species. All ITZ-NPs were nearly spherical with smooth surface 
with a size range of 185–285 nm and zeta potential measured values were close to 
neutrality. In addition, ITZ release showed an initial burst followed by a gradual release 
profile: over 5 days for PEG-g-PLA and over 2 days for PLA-PEG-PLA nanoparticles. Most 
importantly, ITZ-loaded PEG-g-PLA nanoparticles inhibited fungal growth more efficiently in 
specific fungus strains (Candida) than either free ITZ or ITZ-loaded PLA nanoparticles 
suggesting that PEG-g-PLA–ITZ could be used efficiently as a nanocarrier to enhance 
antifungal efficacy (82).  
Likewise, studies carried out by our group revealed that PEG-g-PLA loaded voriconazole 
nanoparticle formulation significantly improved the in vitro antifungal activity against 
Candida ssp (MIC of free voriconazole = 2.917 ± 0.137 mg.L-1, n=3 and MIC of voriconazole-
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loaded-PEG-g-PLA nanoparticles = 0.094 ± 0.01 mg.L-1, n=3). However, just a slightly 
improvement was found in the same test against Candida ssp biofilms (45). 
 
1.3.5. Recent drug carriers and other formulations under development 
The new therapies under development for the treatment of cystic fibrosis are described in 
table VI. 
Table VI: Recent formulations under development for CF treatment. 
Drug Nanocarrier Administration Development 
Amikacin – Aricace ®, 
Insmed Incorporation 
Liposomes Powder for Inhalation Phase III study (83) 
Ciprofloxacin, Aradigm 
Corporation 
Liposomes 
Solution for 
nebulization 
Phase II study (84)  
Ciprofloxacin 
Pulmosphere, Bayer 
Schering Pharma 
Free drug Powder for inhalation. Phase II study (85) 
Fosfomycin/tobramycin 
(Gilead) 
Free drug 
Solution for 
nebulization 
Phase II study (86) 
Levofloxacin solution for 
inhalation (Mpex 
Pharmaceuticals) 
Free drug 
Solution for 
nebulization 
Phase III (87) (88) 
 
The most innovative formulas under development are the amikacin and ciprofloxacin 
liposomal formulations, since the use of a nanocarrier may enable sustained drug release 
(providing decreased side effects and reduced frequency of drug administration). In addition, 
nanocarries may enable mucus penetration thus preventing sub-inhibitory level of 
antibiotics and resulting in decreased bacterial resistance and biofilm formation. These 
benefits provided by nanocarriers may increase the efficacy of the antimicrobial formulation 
against the targeting bacteria; thereby improving the treatment of CF. However the other 
formulations improve the treatment by providing pulmonary administration as compared to 
oral or intravenous administration. 
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2.1. Hypothesis 
Based on the given facts, our hypothesis is that antibiotic-loaded PEG-g-PLA nanoparticles 
may improve the efficiency of the treatment against Pseudomonas aeruginosa in the lungs of 
CF patients, as compared with the free drug. The drugs chosen as models are colistin sulfate, 
tobramycin and levofloxacin, as an attempt to test three different classes of antibiotics 
extensively used for the treatment of CF. 
We predict that PEG-g-PLA engineered nanoparticles may improve the treatment against 
Pseudomonas aeruginosa in Cystic Fibrosis patients based on the following concepts: 
1) Engineered PEG-g-PLA nanoparticles with suitable size and charge are potentially 
mucus penetrating and might increase the targeting of mucus embedded 
Pseudomonas aeruginosa; 
2) PEG-g-PLA nanoparticles might provide extended release of the encapsulated drug 
therefore increasing the exposure of Pseudomonas aeruginosa to therapeutic doses 
of drug and reducing bacterial resistance 
3) PEG-g-PLA nanoparticles have the potential to circumvent bacterial resistance if the 
main mechanism of resistance presented by the strains under analysis is drug efflux 
(as in the case of P. aeruginosa), as have been showed in a precious research carried 
in our laboratory in Candida ssp. and Aspergillus fumigatus strains (45). 
 
2.2. Objectives 
Our main goal is to develop poly(ethylene glycol)-g-poly(lactic acid) (PEG-g-PLA) antibiotic- 
loaded nanoparticles with suitable physicochemical properties for antibiotic delivery in the 
lungs in order to increase the antimicrobial efficiency against Pseudomonas aeruginosa. In 
addition, PEG-g-PLA nanoparticles will be engineered to be mucus inert hence favoring 
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bacterial targeting through improved mucus penetration, as have been earlier discussed in 
the item 3.3.1. 
The overall goal is to produce a solution for nebulization with the potential to be further 
incorporated to a solid vehicle to produce a powder for inhalation. The pulmonary 
administration of an antibiotic aerosolized sustained release formulation may result in 
higher efficiency of treatment and decreased induction of bacterial resistance, as compared 
with the free drug administration by systemic routes (as discussed in the item 1.2.5.2). 
We will essay the encapsulation of tobramycin, colistin sulfate and levofloxacin into PEG-g-
PLA nanoparticles, in order to develop new sustained release formulations. Studies showed 
that after pulmonary administration, levofloxacin reached high sputum and low serum 
concentrations (89). Additionally, higher reduction of P. aeruginosa in sputum and 
improvements in lung function was reached with inhalation if compared with oral 
intravenous administrations. Moreover, levofloxacin appears to be more potent against P. 
aeruginosa biofilms than aminoglycosides and aztreonam (89). Thus, a high and sustained 
level of levofloxacin achievable in the lungs following aerosol delivery of levofloxacin-loaded 
PEG-g-PLA nanoparticles suspension might be useful for the management of pulmonary 
infections caused by P. aeruginosa in CF patients. In addition, the development of PEG-g-PLA 
nanoparticles formulations to encapsulate other drugs such as colistin and tobramycin may 
also be encouraged, therefore targeting different mechanisms of antibiotic action. In fact, 
Pseudomonas aeruginosa has a diversified profile of resistance against many antibiotics 
resulting in an increasing demand of innovative formulations for the treatment of CF. 
In addition, as liposomes have been thoroughly studied and some successful formulations 
for the treatment of cystic fibrosis are under phase III clinical studies (83, 84), we will also 
synthesize and characterize an antibiotic-loaded liposomes formulation (as a positive 
control) and compare their efficiency to kill Pseudomonas aeruginosa in vitro, as compared 
with antibiotic loaded nanoparticles. We hypothesize that nanoparticles will present the 
same or increased activity against P. aeruginosa when compared to liposomes.  
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Thus, the specific objectives at this work are: 1) Synthesize and characterize PEG-g-PLA and 
PLA-OH polymers; 2) Synthesize and characterize tobramycin, colistin sulfate and 
levofloxacin loaded nanoparticles and select the nanoparticle formulation with the highest 
loading efficiency to be further evaluated in microbiological testing; 3) Prepare and 
characterize antibiotic loaded liposomes (same drug as the optimized nanoparticle 
formulation); 4) Evaluate the antibacterial efficiency of antibiotic loaded nanoparticles and 
liposomes as compared to the free drug, through the microbiological susceptibility test in 
the biofilm and planktonic forms of Pseudomonas aeruginosa. 
The description of each step of research for the completion of the specific objectives and the 
respective tests for the characterization of the final products are detailed in table VII. 
Table VII: Plan of work. 
Specific Objective Steps Characterization 
I. Synthesis and 
characterization of PLA-
OH and PEG-g-PLA 
polymer 
Synthesis and characterization of 
polymers. 
Polymer structure: 
1
H NMR 
Polymer Mw, Mn, PDI: GPC 
II. Synthesis and 
characterization of 
antibiotic loaded 
nanocarriers
a
. 
Development of quantitative 
method to dose the antibiotics. 
Quantitative method: HPLC 
HPLC characterization: LOQ, LOD, R
2
. 
Synthesis and characterization of 
polymeric nanoparticles. 
Size and PDI: DLS  
Charge: Zeta Potential. 
Drug loading : HPLC 
Liposomes lipid concentration: Bartlett Assay 
Synthesis and characterization of 
liposomes. 
III. Assessment of free 
antibiotic versus 
antibiotic loaded 
nanocarriers
(a)
 efficiency 
in eradicating planktonic 
and biofilm forms of PA 
in antimicrobial 
susceptibility testing. 
 
Validation of microbiological 
susceptibility tests with free 
antibiotic against PA. 
Broth Microdilution Test (plaktonic form of 
PA). 
Broth Microdilution Test with the Calgary 
Biofilm Device (biofilm form of PA). 
Test the free antibiotic, antibiotic 
loaded and blank nanocarriers
(a)
 
against the planktonic form of 
PA. 
Determine the MIC of free antibiotic as 
compared to antibiotic loaded nanocarriers
(a)
 
to eradicate planktonic PA. 
Test the free antibiotic, antibiotic 
loaded and blank nanocarriers
(a)
 
against the biofilm form of PA. 
Determine the MBIC of free antibiotic as 
compared to antibiotic loaded nanocarriers
(a)
 
to eradicate biofilm of PA. 
aNanocarriers: polymeric nanoparticles and liposomes; PEG: polyethylene glycol; PLA: polylactic acid. NP: nanoparticles; PA: Pseudomonas 
aeruginosa; 1H NMR: Proton Nuclear Magnetic Resonance; PDI: Polydispersity index; GPC: Gel Permeation Chromatography; Mw: weight 
average molecular weight; Mn: number average molecular weight; LOQ: limit of quantification; LOD: limit of detection; R2: correlation 
coefficient (statistics); DLS: Dynamic Light Scattering; HPLC: High Performance Liquid Chromatography; MIC: Minimal Inhibitory 
Concentration; MBIC: Minimal Biofilm Inhibitory Concentration.
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3.1. Synthesis and characterization of PLA-OH and PEG-g-PLA  polymers 
 
i. Materials 
 
3,6-Dimethyl-1,4-dioxane-2,5-dione (dilactide), Benzyl glycidyl ether 99%,Tin(II)-2-
ethylhexanoate 99%, Palladium 5 wt. % activated charcoal, Thionyl Chloride ≥99.0%, 4-
(Dimethylamino) pyridine ≥99% (DMAP), Pyridine anhydrous, 99.8% , Mineral oil, gas 
hydrogen, Celite® Standard Super-Cel®NF acid washed, chloroform, dichloromethane (DCM), 
ethyl acetate, hexane, tetrahydrofuran (THF), dimethyl sulfoxide-d6 99.9 atom % D (DMSO-
d6), chloroform-d were purchased by Sigma-Aldrich (Oakville, ON, Canada). Spectra/Por® 
molecularporus membrane tubing MWCO 6-8000 was supplied by Spectrum Laboratories 
Inc. (Rancho Dominguez, CA, USA). Carboxylmethoxy PEG-2000 (PEG-COOH) was previously 
synthesized as reported in literature (74) and kindly provided by Pr. Hildgen (Université de 
Montréal, QC, Canada). 
 
ii. Methodology 
 
3.1.1. Synthesis of PLA-OH and PEG-g-PLA 
 
3.1.1.1. Synthesis of PLA-BGE 
The polymer poly(ethylene glycol)-g-poly(lactic acid) (PEG-g-PLA) was synthesized following 
the methodology described in Hildgen’s previous publication, with some modifications (74). 
Firstly, PLA was synthesized by the co-polymerization of benzyl glycidyl ether and dilactide 
under argon atmosphere. Briefly, 15 g (0.104 mol) of dilactide previously dried under 
vacuum was mixed with benzyl glycidyl ether (BGE) (4.16 X 10-3 mol, 0.635 mL) and Tin (II)-2-
ethylhexanoate as a catalyst (4.16 X 10-5mol, 0.0135 mL). Then, bulk polymerization was 
carried at 165 ◦C for 15 h. The resulting polymer (PLA-BGE) was purified twice by 
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precipitation in 200 mL of hexane of the crude dissolved in 100 mL of DCM. The residue of 
DCM was removed by evaporation under reduced pressure (Buchi 461 water bath, BÜCHI 
Labortechnik AG, Flawil, Switzerland) and dried under vacuum for two days. The yield 
obtained was 89.5 % (14.03 g of PLA-BGE). Sample of 15 mg was removed for 1H NMR 
analysis which data is found in results session, figure 11. 
 
3.1.2. Synthesis of PLA-OH 
Afterwards, purified PLA-BGE (13 g) was dissolved in 200 mL of ethyl acetate and the benzyl 
group was removed by hydrogenation using bubbling H2 in the presence of palladium 
activated charcoal (2g) for 20 hours in mineral oil bath at 45◦C. According to 1H NMR 
analysis (figure 11), the BGE: PLA ratio obtained in the resulting PLA-BGE polymer was 1%. 
Thus, 13 g of PLA-BGE-(1%) is composed of lactide (12.71 g, 0.176 mol) and BGE (0.29 g, 1.76 
X 10-3 mol). For the hydrogenation, the ratio of 1 g of Pt to reduce 1mM of benzyl group was 
applied (minimal Pt quantity equals to 1.76 g). Therefore, palladium was added in excess to 
assure complete removal of benzyl groups.  
Palladium was removed by filtration on 8 g of Celite® washed with ethyl acetate. Ethyl 
acetate was removed by evaporation under reduced pressure. Purification and drying of the 
resulting polymer PLA-OH was done similarly as PLA-BGE. It was obtained 4.9 g of PLA-OH 
(yield= 38.2%) and sample of 15 mg was withdrawn for 1H NMR analysis which data is found 
in figure 12.  
For the pegylation, firstly PEG-COOH (1.5 g , 7.5 X 10-4 mol) was dissolved in 20 mL of 
chloroform and mixed with thionyl chloride (SOCl2) (5 mL, 0.07 mol) in a round bottom flask 
under magnetic stirring for 2 hours, at room temperature. Chloroform was removed by 
evaporation under reduced pressure in a closed system which enabled the precipitation of 
SOCl2 vapor in a trap with NaOH solution (2 N). The polymer was dried under vacuum 
overnight. Then, PEG-COCl (1.5 g, 7.5 X 10-4 mol) was dissolved in 40 mL of chloroform. To 
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this solution was added the previously synthesized PLA-OH (4.9 g, 0.382 mol and 6.60 X 10-4 
mol of OH groups), anhydrous pyridine (3 mL), DMAP (20.1 mg, 1.65 X 10-4 mol) and the 
reaction was stirred under argon atmosphere and magnetic stirring overnight at room 
temperature. Subsequently, the reaction mixture was extracted three times with 400 mL of 
HCl solution 1N in order to remove non grafted PEG and excess of pyridine. The organic 
phase was collected and chloroform was removed by evaporation under reduced pressure. 
Purification was achieved by dissolving the PEG-g-PLA polymer in 20 mL of DCM and 
precipitating in 40 mL of hexane. After filtration, PEG-g-PLA was dissolved in 40 mL of THF 
and this polymer solution was dialyzed (MWCO 6-8000) against THF (400 mL) of THF for 24 
hours (THF bath was replaced after 12 hours). This last purification step is aimed to remove 
non grafted PEG, given that it is also soluble in the organic solvents used before such as 
chloroform. After 24 hours, THF was removed by evaporation under reduced pressure and 
the purified PEG-g-PLA was dried under vacuum for two days. It was obtained 4.7 g of PEG-g-
PLA polymer (yield of 75%). Samples were removed for 1H NMR (15 mg) (figure 13) and Gel 
Permeation Chromatography (GPC) (2 mg) analysis. 
 
3.1.3. Characterization of PLA-OH and PEG-g-PLA 
The structural confirmation of both polymers was determined by 1H NMR on the Brucker 
ARX 400MHz spectrometer (Bruker Biospin, Billerica, MA). Chemical shifts (δ) were 
measured in parts per million (ppm) using tetramethylsilane as an internal reference. 15 mg 
of PLA-BGE and PEG-g-PLA was dissolved in 0.8 mL of chloroform-d and 15 mg of PLA-OH 
was dissolved in 0.8 mL of DMSO-d6. In addition, to check the polymerization process, Mn, 
Mw and PDI of each polymer (2 mg/mL in THF) was assessed by Gel Permeation 
Chromatography (GPC) in a Waters Associate chromatography system (Waters, Milford, MA) 
equipped with a refractive index detector and a Phenomenex Phenogel of 5 µm column. 
Polystyrene standards were used for calibration with THF as the mobile phase at a flow rate 
of 1 mL/min.  
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iii. Results and discussion 
The synthesis of PEG-g-PLA-2 was realized in three steps: 1) Co- polymerization of PLA and 
BGE to result in PLA-BGE; 2) Deprotection of PLA-BGE to result the PLA-OH; 3) PEG grafting 
to result in the polymer PEG-g-PLA. 
The scheme for the synthesis of PEG-g-PLA-2 is showed in figure 10 and the 1H NMR data for 
the characterization of each sub-product is showed in figures 11, 12 and 13. 
 
Figure 10: Synthesis and 1H NMR characterization of PLA-BGE, PLA-OH and PEG-g-PLA.1 H  
 
NMR analyses were performed to confirm the chemical structures of the polymers 2, 3 and 
4. 
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Figure 11: 
1H NMR spectra of PLA-BGE 
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Figure 12: 
1H NMR spectra of PLA-OH 
 
Figure 13: 
1H NMR spectra of PEG-g-PLA-2 
 
  
38 
 
The peak Hd at 7.3 ppm in figure 11 refers to the 6 aromatic hydrogen groups from the PLA-
BGE (marked with the letter d in the figure 10) and confirms that the benzyl glycidyl ether 
was co-polymerized with the PLA. Each peak of this spectrum was integrated and compared 
with the CH peak from the lactide at 5.1 ppm (Ha) in which was attributed the value of 100% 
to simplify the calculation. As each lactide presents just one group CH (marked with the 
letter a in the figure 10), the integration of the benzyl groups at 7.3 ppm divided by six (since 
it corresponds to 6 hydrogen groups) gives the percentage of grafting of BGE to PLA which 
equals to 1.0 %. The same spectrum also displays the peak at 4.48 ppm which refers to the 
CH2-benzyl group (marked with the letter b in the figure 10), also proving that the co-
polymerization occurred. After hydrogenation the latter peak and the benzyl peak at 7.3 
ppm did not appear in the figure 12, confirming that the hydrogenation reaction successfully 
removed all protecting groups of OH. 
Figure 13 shows the 1H NMR data for the PEG-g-PLA-2, and the peak at 1.45 ppm (Hc) 
corresponds to the CH3 group from the lactide (marked with the letter c in the figure 10). 
However, the ratio of PEG:PLA was calculated by comparing the CH peak of the lactide group 
at 5.2 ppm (100%) (marked with the letter a in the figure 10) with the CH3 final group of the 
metoxy PEG-2000 at 3.38 ppm (marked with the letter e in the figure 10). As the CH3 from 
PEG has three hydrogen groups, the value of its integration was divided by 3 to give the real 
grafting of PEG which equals to 0.4% (1.15%/3 = 0.4%). 
Table VIII shows the 1H NMR data and the results for the GPC analysis for both polymers 
which confirms that the intended syntheses were accomplished. 
Table VIII: Polymers’ batches characterization. 
Polymer Intended grafting (%) Real grafting
a
 Mn
b
 Mw
b
 Mw/Mn
b
 
PEG-g-PLA-1
c
 0.5 0.48 16223 31560 1.9 
PLA-OH
d
 2.0 1.0 25250 37385 1.5 
PEG-g-PLA-2
d
 1.0 0.4 29540 38400 1.3 
aCalculated from peak intensity ratios of PEG at 3.38 ppm in PEG-g-PLA or benzyl at 7.3 ppm in PLA-BGE in relation to PLA at 5.2 ppm from 
1H NMR data. 
bDetermined by GPC analysis using narrow molecular weight polystyrene standards. Mw/Mn= polydispersity index of polymers (PDI).  
cPEG-g-PLA-1 was provided by Patrice Hildgen’s laboratory.dPLA-OH and PEG-g-PLA-2 were synthesized during this study. 
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The PEG-g-PLA-1 was previously synthesized by Hildgen’s group and the batch PEG-g-PLA-2 
was synthesized and characterized during this study, with PLA-OH as an intermediate 
product. According to the 1H NMR analysis data displayed in table XVIII, the accomplished 
PEG grafting ratio for PEG-g-PLA-2 was 0.4%. The possible explanation for the low ratio PEG: 
PLA obtained was that the quantity of PEG-COOH added was not in default as compared to 
the PLA-OH quantity. However, as the molecular weight of PEG is high, even the apparent 
low value of 0.4% can make a difference in the polymer structure adding more hydrophilicity 
to the polymer as aimed, and it is close to batch 1, so good for comparison. 
The GPC analysis provides two ways to express the molecular weight: the number molecular 
weight (Mn) and the weight molecular weight (Mw) and both shows that the polymerization 
successfully occurred and were similar from batch to batch (1 versus 2). The parameter 
(Mw/Mn) designed polydispersity index represents the variation of molecular weight within 
a given population of molecules, and when it is under 0.22 the polymer population can be 
considered as monodisperse. As showed in table VIII, we obtained a polydispersity index 
value of 1.9 for PEG-g-PLA and 1.5 for PLA-OH demonstrating a polydisperse population. 
Indeed, wider dispersion in the molecular weight was obtained for PEG-g-PLA, but it might 
not impair the nanoparticle formulation, since polymeric chains with different sizes can 
easily intercalate to form the nanoparticles. 
In conclusion, 2 reproducible batches of PEG-g-PLA were obtained ready for the nanoparticle 
formulation. The batch of PLA-OH will be used in nanoparticle formulations to modify the 
PLA: PEG ratio and provide OH groups to the polymer, thereby potentially increasing 
hydrophilicity. 
 
 
3.2. Synthesis and characterization of antibiotic loaded nanocarriers 
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3.2.1. Synthesis and characterization of tobramycin, colistin sulfate and 
 levofloxacin nanoparticles 
 
i. Materials 
Tween 20, Span 80, Poly(ethylene glycol) monooleate (PEG-monooleate), Chloroform, 
Ethanol, Dichloromethane (DCM), Isopropanol, Acetonitrile HPLC grade, Trifluoroacetic acid 
(TFA), Phosphoric acid 85%, Triethylamine, Hydrochloric Acid, Sucrose 99%, Fluorescamine, 
Chitosan (Mw 60000-120000), Sodium Alginate, Pluronic F-126, Polyvinyl alcohol2000, 80% 
hydrolyzed (PVA) and Levofloxacin ˃ 98% HPLC grade were purchased by Sigma-Aldrich (St. 
Louis, MO, USA). Tobramycin and Colistin Sulfate were purchased by AK Scientific (AK 
Scientific Inc., Union City, CA, USA), butyl Alcohol was purchased by Anachemia Science 
Canada Inc. (Lachine, QC, Canada) and Spectra/Por® molecularporus membrane tubing 
MWCO 6-8000 was purchased by Spectrum Laboratories Inc. (Rancho Dominguez, CA, USA). 
 
ii. Methodology 
 
3.2.2. Development of quantitative methods to dose antibiotics 
 
3.2.2.1. Development of quantitative method to dose tobramycin 
Tobramycin was analyzed by spectrometry of absorbance in the ultraviolet (UV) after prior 
derivation with fluorescamine (90). Briefly,0.1 mL of tobramycin standard solution and 
samples prepared in water were incubated with 0.1 mL of fluorescamine solution 0.5% (w/v) 
prepared in ethanol. The tobramycin standards for the calibration curve were prepared in 
the concentration of 32, 16, 8, 4, 2, 1 and 0.5 µg/mL. After one hour of incubation at room 
temperature, the absorbance was measured at 390 nm using the Microplate Reader Safire 
(Tecan Group Ltd., Männedorf, Switzerland), fitted out with a 96 well quartz plate.  
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3.2.2.2. Development of quantitative method to dose colistin sulfate 
Colistin sulfate was quantified by High Performance Liquid Chromatography in the Shimadzu 
Prominence Ultra Fast Liquid Chromatogram equipped with Evaporative Light Scattering 
Detection (HPLC-ELSD) (91), since this drug does not present chromophores. All the 
parameters for the test are described in table XI. 
Table IX: HPLC parameters used for the analysis of colistin sulfate 
Column C-18 Zorbax SB (5.0 X 150) mm 
Flow rate 1 mL/min 
Temperature 30ºC 
Mobile Phase 
A = Acetonitrile with Trifluoroacetic Acid (TFA) 37.5 mM                                                                  
B = Deonized water with TFA 37.5 mM 
Gradient From 10% A to 65% A in 6 min. Isocratic for 1 min. From 65% A to 10% A in 2 min. 
Detection ELSD. Temperature of vaporization: 60ºC. Pressure: 3.0 bar. Gain: 7. 
Standards Prepared in the mobile phase. 
Retention time 6.6 and 6.9 minutes (corresponding to Colistin A and B, not necessarily in this order). 
HPLC: High Performance Liquid Chromatography. ELSD: Evaporative Light Scattering Detector. min: minutes. 
 
The plot log of mass (µg) versus log of area provided the calibration curve. The mass could 
be just for the most intense peak of for the sum of both peaks. The Limit of Quantification 
(LOQ) was calculated as LOD= 3.3 (SD/S) and the Limit of Detection (LOD) as LOD=10 (Sd/S) 
where SD is the standard deviation of Y and S is the slop of the curve. 
 
3.2.2.3. Development of quantitative method to dose levofloxacin 
Levofloxacin was quantified by High Performance Liquid Chromatography equipped with 
ultraviolet detection (HPLC-UV) in a Shimadzu Prominence Ultra Fast Liquid Chromatogram 
(92). All the parameters for the test are described in table X. 
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Table X: HPLC parameters used for the analysis of levofloxacin 
Column C- 18 Zorbax SB (5.0 X 150) mm  
Flow rate 1 mL/min 
Temperature 25ºC 
Mobile Phase A = Acetonitrile. B = Phosphoric acid 0.025 M adjusted to pH 3 with trietylamine 
Isocratic 20% A and 80% B for 5 minutes. 
Detection UV = 294 nm 
Standards Prepared in the mobile phase. 
Retention Time 1.7 minutes. 
SB (stable bound). UV: ultra violet. nm:nanometers 
 
The plot concentration (µg/mL) versus area provided the calibration curve. The Limit of 
Quantification (LOQ) was calculated as LOD= 3.3 (Sd/S) and the Limit of Detection (LOD) as 
LOD=10 (Sd/S) where Sd is the standard deviation of Y and S is the slop of the curve. 
 
3.2.3. Organic solvent analysis for drug extraction from nanoparticles 
A biphasic system with organic solvent/ water was used to extract the encapsulated 
hydrophilic drug from nanoparticles. Therefore, the aim of this study was to select the 
appropriate solvent for drug extraction from nanoparticles to ensure that the drug is not 
retained in the organic solvent. Thus, chloroform was analyzed for the extraction of colistin 
sulfate that is insoluble in chloroform. However, as levofloxacin is partially soluble in 
chloroform, its extraction was analyzed in chloroform, ethyl acetate and dichloromethane in 
order to select the best organic solvent. Briefly, drug standard (levofloxacin 10 µg/mL and 
colistin sulfate 200 µg/mL stock solutions were prepared in the aqueous mobile phase 
according to the HPLC method. Then, 1.2 mL of the drug stock solution was extracted by 2 
mL of the selected organic solvent. The biphasic systems were vortexed for 1 minute and 
centrifuged at 2500 r.p.m for 5 min in the Centrifuge IEC Multi® / Multi RF TM (Thermo 
Fisher Scientific Inc.,Waltham, MA, USA). The aqueous supernatant was collected and 
analyzed by HPLC in triplicate. Blanks with mobile phase were also extracted in the organic 
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solvent and compared to the stock solutions and mobile phases without extraction. The 
recovery of drug in the water phase after extraction was calculated by comparing the drug 
peak intensity before and after extraction. Tobramycin is also insoluble in chloroform thus 
this solvent was selected for the extraction without previous solvent analysis. 
 
 
3.2.4. Synthesis and characterization of nanoparticles 
 
3.2.4.1. Synthesis of tobramycin, colistin sulfate and levofloxacin 
 nanoparticles 
Three methods were used for the synthesis of nanoparticles, as described in table XI. 
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Table XI: Applied methodologies for the production of tobramycin nanoparticles. 
Method/ Drug Phases Reagents Methodology 
ESE- Double 
Emulsion (DE) 
w/o/w 
 
Tobramycin
a
 
 
Colistin 
Sulfate
b 
 
Levofloxacin
b
 
1- 
Internal 
water 
phase 
Drug 
Distilled Water 
Phases 1 and 2 were vortexed for 30 seconds. This 
first emulsion was mixed with phase 3 in the high 
pressure homogenizer Emulsiflex C30 (Avestin, 
Ontario, Canada) at 10000 psi for 4 min. NP 
suspension was collected and the organic solvent 
evaporated under reduced pressure for 3 hours. Then, 
NP suspension was centrifuged for one hour at 18500 
r.p.m at 4˚C (Sorval® Evolution RC, Kendro, USA). The 
supernatant was discarded and the NP pellet collected 
and placed in the dialysis bag for 24 hours. After 
dialysis, the purified NP suspension was lyophilized 
(Freeze Dryer ModulyoD-115-230® (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) to recuperate the 
powder of NP. 
2- Oil 
phase 
Mixture of polymers
d
 
or only PEG-g-PLA 
Span 80 (0.4% w/v) 
N-butanol (16.6% w/v) 
Dichloromethane 
3 
External 
water 
phase 
Water 
Tween 20 (2.5% w/v) 
PEG-oleate (0.5% w/v) 
Nano-
precipitation 
(NPP) 
 
Tobramycin
a
 
1- 
Internal 
water 
phase 
Drug 
Water 
First, the oil in water solution was prepared by mixing 
phases 1 and 2 under mixing. This emulsion was 
added to phase 3 under mixing, leading to immediate 
NP precipitation. Afterwards, residual organic solvents 
were extracted by evaporation under reduced 
pressure. NP were isolated by centrifugation at 6000 
rcf for 1 hour at 4˚C (Sorval ® Evolution RC, Kendro, 
USA), dispersed in ultra pure water to a final volume 
of 5 mL, and dialyzed for 24 hours. Different helpers 
were added either in the internal e/or in the external 
water phases (see table XI). 
2- Oil 
phase 
PEG-g-PLA 1% (w/v) 
Dichloromethane 
3 -
External 
water 
phase 
Water/ethanol 50% 
(v/v) 
 
Nano-
precipitation 
(NPP) 
 
Levofloxacin
b
 
1 - Oil 
phase 
Acetone 
Polymer 
Drug 
Phase 1 was dropped into phase 2 under stirring to 
form the NP suspension. Acetone was removed under 
reduced pressure. Then, NP suspension was 
centrifuged for one hour at 18500 r.p.m at 4˚C 
(Sorval® Evollution RC, Kendro, USA). The supernatant 
was discarded and NP collected and dialyzed for 12 
hours. Purified NP suspension was lyophilized in the 
Freeze Dryer ModulyoD-115-230® (Thermo Fisher 
Scientific Inc.,MA, USA) and collected as a powder. 
2- Water 
phase 
Distilled water 
ESE- Single 
Emulsion (SE) 
(o/w) 
Levofloxacin
b
 
1- Oil 
phase 
Polymer, Organic 
solvent
c
, Levo 
Phase 1 was added to phase 2 in the high pressure 
homogenizer Emulsiflex C30 (Avestin, Ottawa, 
Ontario,Canada) at 10000 psi for 4 min. Then, it was 
processed as for the double emulsion. 
2- Water 
phase 
Aqueous surfactant 
solution
e
 
ESE: Emulsification solvent evaporation.aTobramycin NP was synthesized with PEG-g-PLA-1. bColistin Sulfate and Levofloxacin NP were 
synthesized with PEG-g-PLA-2.c Organic solvents tested were DCM or the mixture DCM: DMF (1:1). dMixture of polymers: PEG-g-PLA-2 and 
PLA-OH. eSurfactants used were PVA 0.5 % w/v or the mixture, Tween 20 (2.5 % w/v) and PEG-oleate (0.5% w/v). NP: nanoparticles. PVA: 
polyvinyl alcohol.  
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3.2.4.2. Characterization of nanoparticles 
 
a. Nanoparticle size 
 
After production, the nanoparticle size and the size distribution (the latter expressed by the 
PDI – polydispersity index) were measured at 25˚C and in triplicate (n=3) by Dynamic Light 
Scattering Dynamic Light Scattering (DLS) using the Zetasizer Nano ZS, Malvern (Malvern 
Instruments Ltd, Worcestershire,United Kingdom). Briefly, 0.1 mL of nanoparticles was 
diluted to 1 mL of ultra pure water. 
 
b. Nanoparticle charge 
 
Nanoparticle charge was measured at 25˚C and in triplicate (n=3) in the Zetasizer Nano ZS, 
Malvern (Malvern Instruments Ltd, Worcestershire,United Kingdom). Briefly, 0.1 mL of 
nanoparticle sample was diluted to 1 mL of sodium chloride solution 10 % w/v. 
 
c. Drug content inside nanoparticles 
 
Tobramycin, Colistin Sulfate and levofloxacin loaded nanoparticles were assessed to quantify 
the amount of encapsulated drug. Briefly, approximately 20 mg of nanoparticles were 
weighted and dissolved in 2 ml of chloroform under mixing for 1 minute. To extract the drug, 
1.2 mL of ultra pure water or the respective mobile phase was added in the tobramycin and 
colistin sulfate/levofloxacin tubes respectively. Thus, after 1 minute under vortex a biphasic 
system was formed in each tube which contains the drug in the water phase. Afterwards, the 
biphasic system was centrifuged at 2500 r.p.m for 5 min in the Centrifuge IEC Multi® / Multi 
RF TM (Thermo Fisher Scientific Inc.,Waltham, MA, USA) and the aqueous supernatant was 
collected to be analyzed by absorbance (tobramycin nanoparticles) or by HPLC (colistin 
sulfate and levofloxacin nanoparticles). The encapsulation efficiency (EE) and the loading 
efficiency (LE), were applicable, were calculated as follows: 
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EE =
total quantity of encapsulated drug (mg)
initial quantity of drug (mg)
 x 100 
 =
total quantity of encapsulated drug (mg)
initial quantity of drug (mg) +  initial quantity of polymer (mg)
 X 100 
 
For the calculus of LE, the initial quantity of polymer was calculated as the total amount of 
polymer added in the formulation in mg, since we considered that the yield of the 
nanoparticle production was 100%. Thus, this calculus is accurate for the nanoparticles 
prepared by nanoprecipitation, since the nanoparticle suspension recovery after 
precipitation is 100%. However, for the single and double emulsion method a dead volume 
of nanoparticle suspension is lost inside the homogenizer Emulsiflex C30 (Avestin, Ontario, 
Canada). Therefore, the value of LE calculated for nanoparticles produced by single and 
double emulsion was estimated through this calculation. 
 
 
iii. Results and discussion 
 
3.3. Development of methodologies of analysis to quantify antibiotics 
 
3.3.1. Development of quantitative method to dose tobramycin 
Tobramycin belongs to the aminoglycoside antibiotic class, lacking chromophores for 
ultraviolet (UV) absorption or fluorescent groups. Thus, the derivation of tobramycin with 
fluorescamine enabled its spectrophotometric analysis by absorbance at 390 nm (92). The 
chemical structures of tobramycin and fluorescamine as well as the mechanism of the 
derivation reaction are represented in figure 14. 
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A- Scheme for the chemical reaction in which tobramycin is represented by R-NH2. B: Tobramycin structure. 
A                                                                                          B 
                                                                                             R-NH2 =  
 
Figure 14: Derivation of tobramycin with fluorescamine for spectrophotometric analysis. 
 
The limit of detection (LOD) and the limit of quantification (LOQ) found in this test were 0.5 
and 10 µg/mL, respectively (n=3). The curve was linear between 0.5 to 64 µg/mL with the 
equation of y= 0.0245x - 0.0065 and R2= 0.9999. 
 
3.3.2. Development of quantitative method to dose colistin sulfate 
Colistin is a cationic cyclic decapeptide linked to one of the two different fatty acid chain to 
form Colistin A or Colistin B (42) as showed in figure 15.  
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Figure 15: Chemical structure of colistin and colistimethate sodium. The fatty acid molecule is 6-
methyloctanoic acid for colistin A and 6- methylheptanoic acid for colistin B. a and g indicate the respective -NH2 involved in the peptide 
linkage. Dab, diaminobutyric acid; Leu, leucine; Thr, threonine. Taken from reference (42). 
 
The mixture of Colistin A and B is commercially available in the salt form of colistin sulfate 
and colistimethate sodium. Colistimethate sodium is generally administrated by nebulization 
in the treatment of CF, since colistin sulfate causes throat irritation and severe cough (93). 
Thus, we first tried to develop an HPLC method for the quantification of colistimethate 
sodium (data not presented). However, the high hydrophilicity of colistimethate sodium 
prevents its retention on the reverse phase column (C18) so the drug is eluted too early. In 
normal phase (Hydrophilic Interaction Column - HILIC), the drug has such a high affinity for 
the stationary phase that it cannot be completely washed from the column. Another 
drawback is that colistimethate sodium is a pro-drug for colistin sulfate; therefore, it can 
undergo hydrolysis in aqueous medium. In this regard, we decided to select colistin sulfate 
as a model drug since this antibiotic is stable in water and less hydrophilic than 
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colistimethate sodium, thus favoring its HPLC analysis and encapsulation in the hydrophobic 
matrix of PEG-g-PLA polymer. 
Colistin sulfate presented two peaks found between 6 and 7 minutes (figure 16) which 
corresponds to colistin A and colistin B (not identified/ assigned). The calibration curve can 
be calculated either based on the sum of the two peaks or just based on the most intense 
peak. The linearity was obtained in the range of 40 to 160 µg/mL. The limit of detection is 40 
µg/mL. The limit of quantification for the analysis with both peaks is 60 µg/mL (with the 
equation of y= 1.7121x + 5.0278, R2= 0.9985) and for the analysis considering just the most 
intense peak is 40 µg/mL (with the equation of y= 1.6484x + 4.9567, R2= 0.9992). Thus, the 
calibration curve was set with the mass of the most intense peak (single peak instead of both 
peaks) which allowed the quantification of lower concentrations of colistin sulfate. Indeed, 
the values of LE and EE obtained for multiple batches of colistin sulfate were sometimes 
lower even than the lowest limit of quantification provided by the calibration curve 
considering the most intense peak. 
 
Figure 16: Colistin sulfate peaks at 6.6 and 6.9 minutes from the HPLC-ELSD analysis.  
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3.3.3. Development of quantitative method to dose levofloxacin 
Levofloxacin (figure 17) has chromophores in its structure thus it is easily detected by UV at 
294 nm. Levofloxacin displayed a single peak at 2.7 min (figure 18). The linearity was 
obtained in the range of 0.5 to 20 µg/mL (with equation of y= 95332x – 1555, R2 ≥ 0.999). 
The limit of detection (LOD) was 0.1 µg/mL and the limit of quantification (LOQ) was 3.0 
µg/mL with n=9. 
 
Figure 17: Chemical structure of levofloxacin. Taken from reference (94). 
 
Figure 18: Levofloxacin peak at 2.7 minutes from the HPLC-UV analysis. 
 
3.3.4. Organic solvent analysis for the drug extraction from nanoparticles 
The results for the levofloxacin (10 µg/mL) recovery after drug extraction in 
dichloromethane, chloroform and ethyl acetate and the recovery of colistin sulfate (100 
µg/mL) from chloroform are described in the table XII. 
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Table XII: Analysis of organic solvents for drug extraction of levofloxacin and colistin sulfate 
from nanoparticles. 
Solvent Levofloxacin Recovery (%)
a
 Colistin Sulfate Recovery (%)
b
 
Dichloromethane 87.9 ± 5.7 - 
Chloroform 96.9 ± 0.1 94.91 ± 1.7 
Ethyl Acetate 96.5 ± 0.2 - 
a
Extraction made in triplicate and each test was injected in triplicate for HPLC analysis (n=9). 
b
Extraction made in duplicate and each test was injected in triplicate for HPLC analysis (n=6). 
 
As displayed in table XII, levofloxacin exhibited the highest percentage of recovery in the 
water phase when extraction was made with chloroform and ethyl acetate. However, ethyl 
acetate was not selected for nanoparticle extraction due to problems with the separation of 
phases after centrifugation. In fact, an emulsion was formed in the interface water/ethyl 
acetate. Besides, ethyl acetate is less dense than water and these both drawbacks hindered 
the collection of pure water phase for HPLC analysis. Therefore, the presence of impurities 
was detected in the samples since the HPLC chromatogram showed two overlapping peaks 
with the same retention time as levofloxacin. So we selected chloroform for the extraction 
of levofloxacin. However, knowing that levofloxacin is partially soluble in chloroform, the 
standards and samples were treated with the same method of extraction. Indeed, even if 
part of levofloxacin was lost in the organic phase, the same drug ratio would be lost in the 
standards solutions and in the samples, thus minimizing errors in the drug quantification. 
DCM was not considered a better option since the percentage of recovery was lower than 90 
%. 
As colistin sulfate is not soluble in chloroform, we decided to use the same solvent for 
nanoparticle extraction after checking the efficiency of drug recovery, as showed in table XII. 
This checking was not done for tobramycin but it is also insoluble in chloroform which was 
used for drug extraction. 
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3.3.5. Synthesis and characterization of nanoparticles 
 
3.3.5.1. Process of nanoparticle production 
Several techniques have already been developed for nanoparticle production. However, the 
physicochemical properties of the drug and the polymer must be taken into consideration 
for the choice of the best method, in order to achieve an efficient drug entrapment. In this 
work we will discuss the nanoparticle preparation by the use of two techniques: 
emulsification solvent evaporation – ESE (single and double emulsion) and nanoprecipitation 
(NPP). 
The single emulsification solvent evaporation technique is divided in two steps. First, the 
polymer and the drug are dissolved in an organic phase which is further emulsified in water 
by high pressure homogenization to prepare the emulsion oil in water (o/w). Afterwards, the 
organic solvent is evaporated inducing polymer precipitation as nanospheres or 
nanocapsules.  
The nanoprecipitation technique (also known as solvent displacement) requires the 
dissolution of the drug and polymer in a water miscible organic solvent and its further 
precipitation in the water phase. In this case, the diffusion of the water-miscible solvent in 
water causes the precipitation of the polymer which is insoluble in water and the 
instantaneous entrapment of the drug. The organic solvent is further evaporated. 
However, both mentioned methods are more efficient to encapsulate hydrophobic drugs 
and the drugs used in the treatment of the cystic fibrosis are generally hydrophilic.  
As an alternative, a modification on the single emulsification- solvent evaporation technique 
has led to the protocol favored for encapsulating hydrophilic drugs: the double emulsion 
technique. First, the hydrophilic drug is dissolved in water with a stabilizer. The first 
emulsion is formed by dispersing this inner aqueous phase into an organic solvent containing 
the dissolved polymer. Then, the first emulsion is emulsified by high pressure 
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homogenization in an outer water phase with stabilizers to form the water/oil/water 
emulsion (w/o/w).  
 
3.3.5.2. Synthesis and characterization of tobramycin loaded nanoparticles 
The composition and characterization of tobramycin nanoparticle batches are described in 
table XIII. 
Table XIII: Composition and characterization of tobramycin nanoparticles batches. 
Batches
a
 Method 
Drug 
(w/w) 
(%)
b
 
Volume of 
the organic 
phase (mL) 
Volume of 
the water 
phase 
(mL)
c
 
Additive 
in the 
water 
phase 
Size (nm)
d,e
 PDI
d,e
 
EE 
(%)
f
 
LE 
(%)
g
 
TB_DE_1 DE 9 20 
1   (I) 
160 (O) 
- 126.5 ± 0.8 
0.249 
± 
0.001 
- - 
TB_DE_2 DE 11.25 16 
1   (I) 
160 (O) 
Sucrose 
5 % (w/v) 
(O) 
251.1 ± 3.4 
0.19± 
0.03 
- - 
TB_DE-3 DE 3.5 16 
1   (I) 
160 (O) 
Sucrose 
5 % (w/v) 
(O) 
155.4 ± 3.1 
0.260
± 
0.008 
- - 
TB_NP_4 NPP 2 1 
0.1 (I) 
200 (O) 
SA (I)
i
 
CH (O)
h
 
Ethanol 
50% v/v
 
 
140.4 ± 2.2 
0.12± 
0.02 
- - 
TB_NP_5 NPP 2 1 
0.1 (I) 
200 (O) 
SA (I)
i
 
PVA
j 
Ethanol 
50% v/v 
205.0 ± 6.8 
0.23 
± 
0.01 
- - 
a
PEG-g-PLA-1was used in each batch. 
b
Ratio of drug weight and polymer weight by percentage. 
c
 Volume of water present in 
the inner phase (I) and in the outer phase (O). 
d
All values indicate mean ± SD for n=3 independent measurements for the 
same batch. 
e
Measured by Dynamic Light Scattering (DLS). 
f
Encapsulation Efficiency (EE): (Total quantity of drug 
encapsulated/ Total amount of drug added) * 100. 
g
Loading Efficiency (LE): Total quantity of drug encapsulated / (Total amount of drug added + Total amount of polymer)*100 
h
CH: Chitosan (1:20) (helper polymer / PEG-g-PLA ratio (w/w). 
i
SA: Sodium alginate 0.04% (w/v). 
j
PVA: Polyvinyl alcohol (PVA/PEG-g-PLA-1 3:5 w/w) 
TB: tobramycin; NP: nanoparticles; DE: double emulsion; NPP: nanoprecipitation; PDI: polydispersity index. 
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As can be showed in table XIII, even with the modification of parameters such as method of 
nanoparticle preparation, drug to polymer ratio, and inclusion of additives, nanoparticles 
were obtained in the appropriate size range for mucus penetration (67). However, the issue 
was the tobramycin encapsulation efficiency that remained lower than the HPLC limit of 
quantification despite further optimization. 
The first nanoparticle method explored to produce tobramycin nanoparticles was the double 
emulsion technique. This method favors the encapsulation of the hydrophilic drug as 
compared with the single emulsion, since the drug is first entrapped within the polymer in 
the first emulsion w/o. Thus, the interaction of the drug with the polymer in the first 
emulsion decreases the chance of drug migration into the external water phase, as 
compared with the single emulsion process. In the batch 1, no tobramycin was detected in 
the spectrophotometric assay with fluorescamine. Thus, in the batch 2 the quantity of drug 
was increased and sucrose 5% (w/v) was added to the external water phase as an attempt to 
decrease drug leakage by equilibrating the osmotic pressure and viscosity. As no 
improvement in the encapsulated drug content was observed, the quantity of drug in the 
internal water phase was decreased as an attempt to decrease the difference of ionic 
strength between inner/outer water phase, and the concentration of sucrose was 
maintained at 5% w/v. However, no substantial difference was verified in the intensity of the 
OD (optical density) found in the quantification assay for the nanoparticle samples.  
As an alternative to overcome this low drug entrapment, we also produced nanoparticles by 
nanoprecipitation. In the second methodology, polymers were added in the inner and/or 
outer phase as helpers to increase tobramycin encapsulation (90). In the batch 4, chitosan 
was added in the outer phase with the ratio of 1:20 (helper polymer / PEG-g-PLA ratio 
(w/w)). We predicted that chitosan have a better effect in reducing drug migration to the 
outer aqueous phase since it has higher molecular weight and concentration when 
compared with the sucrose previously used. In addition, chitosan has a positive charge in 
solution, such as tobramycin, thus resulting in an electrostatic repulsion of tobramycin and 
its migration to the inner aqueous phase. Conversely, in the batch 5 PVA was added in the 
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outer phase as a non-ionic stabilizer. In the batches 4 and 5 sodium alginate was added in 
the inner water phase as an attempt to attract tobramycin in the inner phase since sodium 
alginate is negatively charged in solution and tobramycin is positively charged. However, 
these changes showed to be inefficient to increase the drug loading.  
The methodology to quantify tobramycin according to the United States Pharmacopeia and 
National Formulary (USP 29 – NF 24) (95) is by HPLC using pre-column derivatization with 
2,4- Dinitrofluorobenzene (DNFB) which has limit of quantification of 3 µg/mL (96). However, 
we chose to apply a simpler method to quantify tobramycin such as spectrophotometry 
using fluorescamine as a derivatizing agent (97) which showed similar limit of quantification 
of 3 µg/mL. However, the LE and EE of tobramycin obtained inside nanoparticles was even 
lower than the 3 µg/mL indicating that the values of LE and EE calculated were not 
trustworthy and that the development of a new quantification method with higher 
sensitivity was required, prior to continuing with further optimization of nanoparticle 
production. 
As a consequence, we tried to develop other method of quantification such as LC/MS/MS 
and bioluminescence. However, the drug interacted with the HPLC steel stainless material so 
that it was impossible to get a linear calibration curve. For the bioluminescence assay, the 
calibration curve did not showed linearity, pointing to some unknown interferences. Thus, 
we decided to screen another drug model for the nanoparticle formulation with a higher 
limit of detection in order to facilitate our analysis on the drug loading. In addition, this 
model drug should be less hydrophilic than tobramycin in order to increase its affinity for 
PEG-g-PLA polymer which is hydrophobic.  
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3.3.5.3. Synthesis and characterization of colistin sulfate and levofloxacin 
 nanoparticles 
 
Several batches of nanoparticles were synthesized and characterized regarding to size, 
charge and drug content with the objective to improve the encapsulation efficiency of 
colistin sulfate and levofloxacin, as describe in tables XIV and XV. 
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Table XIV: Composition of colistin sulfate and levofloxacin nanoparticle formulations. 
Nº NP formulation
a
 Method Drug 
Theoretical 
LE  
(w/w) %
b
 
Rational 
1 
PEG-g-PLA (70%) +                                       
PLA-OH (30%)
 DE C 7.3 
Add PLA-OH to enable hydrogen bonds with L 
thus favoring drug entrapment inside NP.  
2 
PEG-g-PLA
 
(30%) +                                       
PLA-OH (70%) 
DE C 0.5 Increase the percentage of PLA-OH. 
3 
PEG-g-PLA (50%) +                                   
PLA-OH (50%) 
DE C 5.0 
Surfactants in the oil phase were twice the 
regular concentration. The external water 
phase contains sucrose 10% w/v. 
4 PEG-g-PLA (100%) SE C 10.0 
DCM as organic solvent. PVA 0.5% (w/v) as 
surfactant. Lauric acid 6% (w/w)
c
. 
5 PEG-g-PLA (100%) SE C 10.0 
DCM: DFM (1:1) as organic solvent. PVA 0.5% 
(w/v) as surfactant. Lauric acid 6% (w/w)
c
. 
6 PEG-g-PLA (100%) SE C 10.0 
DCM: DFM (1:1) as organic solvent. Tween 20 
(2.5 % w/v) and PEG-oleate (0.5% w/v) as 
surfactant. Lauric acid 6% (w/w)
c
. 
7 PEG-g-PLA (100%) NPP L 5.0 Water phase adjusted to pH 4.6 with HCl. 
8 PEG-g-PLA (100%) DE L 0.5 Regular formulation 
9 PEG-g-PLA (100%) SE L 2.0 Addition of PVA 0.5% w/v in the water phase. 
10 PEG-g-PLA (100%) NPP L 5.0 Water phase composed of 50% ethanol. 
11 PEG-g-PLA (100%) NPP L 5.0 Water phase composed of 50% isopropanol. 
12 PEG-g-PLA (100%) NPP L 5 Water phase composed of ethanol 10% v/v. 
13 PEG-g-PLA (100%) NPP 
L 
5 
Water phase composed of 10% ethanol and 
1.1% w/v surfactant Pluronic F-127. 
14 PEG-g-PLA (100%) NPP 
L 
5 
Water phase with pH adjusted to 4.6 with HCl 
and ethanol concentration of 20% v/v. 
15 PEG-g-PLA (100%) NPP 
L 
5 
Water phase with pH adjusted to 4.6 with HCl 
and ethanol concentration of 30% v/v. 
16 PEG-g-PLA (100%) NPP 
L 
5 
Water phase with pH adjusted to 4.6 with HCl 
and ethanol concentration of 40% v/v. 
17 PEG-g-PLA (100%) NPP L 5 Distilled water. 
18 PEG-g-PLA (100%) NPP 
L 
5 
Water phase with sucrose 10% w/v and 
ethanol concentration of 50% v/v. 
19 PEG-g-PLA (100%) NPP L 5 Water phase with sucrose 10% w/v. 
20 PEG-g-PLA (100%) NPP L 0.5 Water phase composed of 50% ethanol. 
21 PEG-g-PLA (100%) NPP L 2.0 Water phase composed of 50% ethanol. 
22 PEG-g-PLA (100%) NPP L 10.0 Water phase composed of 50% ethanol. 
a
PEG-g-PLA-2 was used in each batch.
b
mg of drug per 100 mg of polymer. 
c
mg of lauric acid per 100 mg of polymer. 
SE: single emulsion. DE: double emulsion; NPP: nanoprecipitation; LE: loading efficiency; NP: nanoparticles. 
C: Colistin sulfate; L: levofloxacin. PVA: polyvinyl alcohol. DMF: Dimethylformamide. 
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Table XV: Characterization of colistin sulfate and levofloxacin nanoparticle formulations 
Nº NP formulation 
Hydrodynamic 
diameter (nm)
a,b
 
Drug 
Polydispersity 
index
a.b
 
Zeta potential 
(mV)
a,b
 
LE (%)
c
 EE (%)
d
 
1 
PEG-g-PLA (70%)      
+                                       
PLA-OH (30%)
 
172.8* C 0.622* -11.8 ± 8.10 
No 
peak 
- 
2 
PEG-g-PLA (30%)      
+                                       
PLA-OH (70%) 
131.6 ± 0.8 C 0.170 ± 0.010 -8.67 ± 6.1 
Peak 
not 
quantifi
a-ble 
- 
3 
PEG-g-PLA (50%)      
+                                       
PLA-OH (50%) 
121.3* C 0.205* -10.9 ± 7.37 
No 
peak 
- 
4 PEG-g-PLA (100%) 131.1 ± 6.5 C 0.238 - 0.0127 0.1681 
5 PEG-g-PLA (100%) 116.2 ± 1.9 C 0.222 - 0.0053 0.0724 
6 PEG-g-PLA (100%) 166.6 ± 3.4 C 0.331  0.0028 0.0273 
7 PEG-g-PLA (100%) 121.1 ± 1.3 L 0.140 ± 0.01 -28.2 ± 0.6 
0.0019
5 
0.04 
8 PEG-g-PLA (100%) 131.6 ± 2.4 
L 
0.170 ± 0.021 -8.67 ±0.6 
No 
peak 
- 
9 PEG-g-PLA (100%) 109.4 ± 2.5 
L 
0.086 ± 0.015 - 
No 
peak 
- 
10 PEG-g-PLA (100%) 85.1 ± 3.0 L 0.101 ± 0.043 - 0.0245 0.4897 
11 PEG-g-PLA (100%) 82.1 ± 1.5 L 0.144 ± 0.029 - 0.0120 0.2391 
12 PEG-g-PLA (100%) 114.8 ± 2.9 L 0.26 ± 0.010 -5.33 ± 6.36 0.0160 0.3203 
13 PEG-g-PLA (100%) 112.0 ± 5.5 L 0.088 ± 0.018 -2.64 ± 9.13 0.0025 0.0504 
14 PEG-g-PLA (100%) 137.9 ± 1.7 L 0.125 - 0.0018 0.00009 
15 PEG-g-PLA (100%) 134.5 ± 1.7 L 0.203 ± 0.006 - 0.0047 0.00023 
16 PEG-g-PLA (100%) 110.6 ± 2.1 L 0.197 ± 0.027 - 0.0047 0.00023 
17 PEG-g-PLA (100%) 118.9 ± 1.0 
L 
0.176 ± 0.021 -3.0 ± 16.0 
No 
peak 
No peak 
18 PEG-g-PLA (100%) 157.2 ± 8.3 L 0.174 ± 0.045 -7.97 ± 7.76 0.001 0.0193 
19 PEG-g-PLA (100%) 142.4 ± 3.3 L 0.223 ± 0.045 -1.44 ± 4.07 0.001 0.0206 
20 PEG-g-PLA (100%) 153.1 ± 7.9 
L 
0.256 ± 0.024 - 
No 
peak 
- 
21 PEG-g-PLA (100%) 127.4 ± 7.6 
L 
0.188 ± 0.051 - 
No 
peak 
- 
22 PEG-g-PLA (100%) 95.9 ± 1.2 L 0.083 ± 0.005 - 0.001 0.01 
a
All values indicate mean ± SD for n=3 independent measurements for the same batch. 
b
Measured by Dynamic Light Scattering (DLS). 
c
Encapsulation Efficiency (EE): (Total quantity of drug encapsulated/ Total amount of drug added) * 100. 
d
Loading Efficiency (LE): Total quantity of drug encapsulated / (Total amount of drug added + Total amount of polymer)*100 
*n=1. 
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The results in the table XV show that the nanoparticle size achieved by either NPP or ESE 
was ˂ 200 nm in accordance with the literature to achieve eﬃcient diﬀusion in the mucus 
(67). In addition, the PDI was lower than 0.2 which means a considerable low polydispersity 
of size, since particles with PDI˂ 0.1 are considered to have monodisperse distribution of 
size.  
The zeta potential obtained for each batch is also displayed in table XV. All formulations 
exhibited zeta potential varying from (-1.44 which may be considered neutral) to -28.2 mV. 
According to the literature, particles with neutral charge present better penetration in the 
mucus (67, 77, 98, 99). Thus, the external charge found in our nanoparticles would not favor 
nanoparticle diffusion in the mucus. The reason for the negative surface is the carboxylic 
acid end groups of PLA. The external covering of PEG in the nanoparticles might shield this 
negative charge, but not completely. Although we have not produced blank nanoparticles, 
the literature shows that PEG-g-PLA blank nanoparticles exhibited charge of -1.30 mV but 
the formulation was different. Thus, for blank nanoparticles we expect neutral or slightly 
negative charge (79). 
To increase the LE we modified: 
a. Polymer composition 
As described in table XIV, colistin sulfate nanoparticles were produced by double emulsion 
(emulsification- solvent evaporation technique - ESE). As the previous production of 
tobramycin loaded NP with PEG-g-PLA presented low loading efficiency (LE), based on the 
literature review we predicted that the addition of a polymer with higher hydrophilicity 
could improve the entrapment of such a drug. According to the literature, levofloxacin has 
already been encapsulated into PLGA nanoparticles (100) (101) with LE of 1,1 and 7.9 % w/w 
respectively. However, the polymer used in these works was PLGA 50/50 (DL-lactide/ 
glycolide) copolymer acid terminated, which is more hydrophilic than PLA based 
nanoparticles. Indeed, studies have showed that the component in the nanoparticle 
formulation which mainly impacts the LE of hydrophilic drugs is the hydrophilicity of the 
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polymer. Therefore, polymers with higher affinity for the drug will enhance drug loading. For 
instance, Barichello et al, tried to encapsulate lipophilic drugs (valproic acid, indometacin 
and cyclosporine A), hydrophilic drugs (vancomycin and phenobarbital) and ketoprofen (a 
drug sparingly soluble in water) in PLGA 75: 25 (DL-lactide/ glycolide) (102). The results of LE 
obtained confirmed the hypothesis that the most hydrophobic drugs would achieve the 
highest LE due to the hydrophobic nature of the polymer. Thus, favored interactions 
between drug and polymer would decrease drug leakage during nanoparticle formation. 
Following the same rationale, Cheow et al tried to encapsulate levofloxacin in PCL 
(polycaprolactone) and PLGA 50/50 (DL-lactide/ glycolide) .by NPP and ESE (single emulsion). 
In fact, PCL is a polymer less hydrophilic than PLA. Thus, the LE (% w/w) obtained with the 
nanoprecipitation method was 0.4 and 0.65 respectively. In addition, higher LE was obtained 
with PLGA by ESE (1.1 % w/w) (103). 
Thus, PLA-OH was introduced in the batch 1 with concentration of 30% as an attempt to 
favor hydrogen bonds with levofloxacin and the drug entrapping inside the polymeric matrix. 
However, as showed in table XV, no peak was detected for the nanoparticles analysis by 
HPLC. Afterwards, we synthesized batch 2 with 70 % of PLA-OH and batch 3 with 50% of PLA-
OH. However, the results of EE remained low suggesting that the addition of PLA-OH did not 
significantly altered the overall lipophilicity of the system and/ or did not increase the 
colistin affinity for the polymer mixture. In fact, Hammady et al (54), succeeded to 
encapsulate the hydrophilic calf thymus DNA in PEG-PLA block polymers. However, despite 
the difference of polymer morphology, calf thymus DNA is a bigger molecule with mean 
molecular weight of 8,418,000 (g/mol) if compared to colistin sulfate 1267.6 g/mol. In fact, 
the leakage of hydrophilic drugs to the external water phase is related with drug diffusion 
which is higher with small molecules, as seen with colistin. Thus, the encapsulation of calf 
thymus DNA in PEG-PLA block polymers might have been favored by its high molecular 
weight.  
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b. Surfactants composition 
In the same work (54), Hammady emphasized the role of the surfactants to stabilize the first 
emulsion and avoid drug leakage. Thus, as our polymer presents different morphology, we 
tried to increase the quantity of surfactants in batch 3, without success. As the optimization 
of the NPP method is more complex if compared with ESE, and the first method does not 
offer advantages over the latter to encapsulate hydrophilic drugs; we decided to continue 
the optimization process with ESE by single emulsion. 
 
c. Solvents and co-solvents in ESE by single emulsion 
The aim in the batches 4, 5 and 6 was to verify if the mixture of DCM: DMF (1:1) could 
improve the LE. The rationale is to decrease the hydrophobicity of the organic phase by 
adding DMF which is more polar than DCM. Therefore the drug diffusion for the water phase 
should be decreased. In addition, the impact of two different surfactants was also verified. 
Most importantly, lauric acid was added as an attempt to form ion pairing with colistin 
sulfate thus hindering drug efflux to the water phase as demonstrated before by. Govender 
et al (104). In this work the approaches investigated for LE enhancement included the 
influence of aqueous phase pH, replacement of procaine hydrochloride with procaine 
dihydrate and the inclusion of helpers: (PLA) oligomers, poly(methyl methacrylate-co-
methacrylic acid) (PMMA–MA) or fatty acids into the formulation. Helpers were added to 
determine if an increased content of carboxyl groups in the matrix could increase the 
entrapment of the cationic drug. It was found that aqueous phase pH of 9.3, replacement of 
procaine hydrochloride with procaine dehydrate (less hydrophilic) and the incorporation of 
PMMA–MA, lauric and caprylic acid into the formulation enhanced LE.  
In fact, we probably varied too many parameters in a few batches. But the LE results 
exhibited in table XV showed that lauric acid might have improved the encapsulation of 
colistin sulfate if compared with the double emulsion method since we were able to detect a 
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peak and calculate the levofloxacin concentration. However, the mixture of solvent seemed 
less efficient to increase LE if compared with DCM. A possible hypothesis is that DCM 
improved lauric acid solvatation, lauric acid thus aiding the formation of the ion- pair if 
compared with the more hydrophilic organic phase formed by the mixture DCM/DMF. Most 
importantly, the application of the single emulsion method and other artifices (ion pairing, 
organic solvent polarity and use of different surfactants) was not efficient to significantly 
increase the LE of colistin sulfate in PEG-g-PLA nanoparticles. 
 
d. Nanoparticle formation method 
Afterwards, we followed with the production of levofloxacin nanoparticles by 
nanoprecipitation, double emulsion and single emulsion (batches 7, 8 and 9 respectively) as 
exhibited in table XIV. As the best result for EE so far was found with levofloxacin 
nanoparticles by nanoprecipitation showed in table XVI line 10, we decided to select this 
drug as a model drug for our polymer and to follow further optimizations with the NPP 
technique. Other reasons that guided our choice to work with levofloxacin are: 1) The HPLC 
test to quantify levofloxacin possess lower LOQ if compared with the HPLC method to 
quantify colistin sulfate which is important to evaluate improvements in the low EE in each 
batch; 2) Levofloxacin (log P = -2.1) (105) is less hydrophilic than colistin sulfate (log P = -3.15 
for colistin A and log P= -3.60 for colistin B) (106), thus we hypothesized that levofloxacin 
might have higher affinity to PEG-g-PLA. 3) Colobreathe® study showed little improvement in 
FEV1 with colistin dry powder treatment compared to tobramycin(30). Therefore, 
levofloxacin is more appropriate than colistin to be further formulated as a powder to 
inhalation to treat cystic fibrosis. . 
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e. pH 
Besides polymer composition, the variation of other parameters has also been studied as an 
attempt to increase the LE of hydrophilic drugs. For example, Mobarak et al tried to improve 
the LE of ciprofloxacin hydrochloride in PLGA (50: 50) by the double emulsion solvent 
evaporation technique (107). The variation of three different variables was evaluated: 1) 
application of probe sonication besides the high pressure homogenization and during the 
solidification step; 2) effect of polyvinyl alcohol addition in the formation of the o/w primary 
emulsion; 3) addition of sodium chloride in the external and extraction water phase; 4) pH 
adjustment of the external and extraction phases to 7.4. The best EE achieved was with the 
use of sodium chloride, buffer, and PVA. Sodium chloride adjusted the osmotic pressure in 
the external water phase in order to avoid drug leakage, pH adjustment to the least 
solubility of ciprofloxacin favored polymer/drug affinity and PVA was added to stabilize the 
first emulsion o/w thus, enhancing the drug entrapment. Besides, the sonication during 
solidification step did not increase the EE. However, the use of sonication in addition to 
homogenization to form the secondary emulsion helped to enhance the LE. 
The pH impact on LE was also analyzed in our work. However, the results for the LE of 
batches 7 and 17 did not show a significant improvement in the LE. In fact, later it was 
checked that the lowest solubility of levofloxacin is at pH between 7 and 8 (105). Therefore, 
the best option should have been to adjust the water phase at pH=7.4 to have a better 
impact in the LE (decrease its solubility in the diffusion water phase thus decreasing 
leakage). 
 
f. Co-solvents in NPP 
In batches 10 and 11, water miscible co-solvents (ethanol and isopropanol respectively) 
were added in the diffusion phase water with the attempt to decrease the solubility of 
levofloxacin thus preventing drug diffusion. Actually, the best EE was reached with the batch 
10. 
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g. Additives in NPP 
Thus, in batches 12 and 13 we evaluated if the ethanol concentrations could be optimized to 
enhance LE. Besides, the impact of surfactant incorporation in the LE was also evaluated. In 
the formulations 14 to 17 we evaluated the impact of ethanol concentration and pH in the 
EE. However, the best conditions were in formulation 10. In batches 18 and 19, we evaluated 
the impact of adding a non ionic component in the diffusion phase in order to concentrate it, 
thus avoiding drug migration due to ionic strength. 
 
h. Drug feeding ratio 
Finally, as there was no improvement with any of these changes, we kept the parameters of 
batch 10 and varied the drug concentration in batches 17-19 with no success. However, the 
best LE achieved by levofloxacin encapsulation in PEG-g-PLA was 0.02% with the addition of 
ethanol 50% v/v in the external water phase of nanoprecipitation. 
To conclude, the parameters used for the encapsulation of tobramycin, colistin sulfate and 
levofloxacin in PEG-g-PLA have already been used successfully to enhance the encapsulation 
of other hydrophilic drugs, mostly in PLGA matrices. Although we obtained nanoparticles 
with suitable size and polydisperity index for drug delivery in the mucus, the zeta potential 
obtained was negative, a fact that could hinder nanoparticles diffusion in the mucus. Most 
importantly, the LE obtained was low, probably due to low affinity of PEG-g-PLA and or PLA 
polymers to the hydrophilic drugs. New batches with pH optimization could be tested, since 
the pH range tested does not reflect the best difference in the drug solubility. 
Indeed, as drug entrapment into liposomes does not depend on the interaction of drug and 
lipids, levofloxacin loaded liposomes will be synthesized and characterized as an attempt to 
develop a formulation with suitable drug loading to be tested in Pseudomonas aeruginosa to 
fulfill the objectives proposed for this work. 
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3.4. Synthesis and characterization of levofloxacin loaded liposomes 
 
i. Materials 
Methanol, acetonitrile, acetone, phosphorus standard solution 0.65 mM (phosphorus as 
KH2PO4 20 μg/mL in 0.05 N HCl), ammonium molybdate, ammonium sulfate, sodium 
metabisulfide, ascorbic acid, sulfuric acid, hydrogen peroxide, levofloxacin ˃ 98% HPLC 
grade, sodium chloride (NaCl) and cholesterol were purchased by Sigma-Aldrich (Oakville, 
ON, Canada). 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene-glycol)-2000] (DSPE-PEG(2000)-
biotin) were obtained from Avanti Polar Lipids. Amicon Ultra-15 Centrifugal Filter Unit with 
Ultracel-10 membrane was obtained by EMD Millipore Corporation (Billerica, MA, USA). 
Spectra/Por® molecularporus membrane tubing MWCO 6-8000 was purchased by Spectrum 
Laboratories Inc. (Rancho Dominguez, CA, USA). 
 
 
ii. Methodology 
 
3.4.1. Preparation of liposomes 
Blank and levofloxacin loaded liposomes composed of DSPC/Cholesterol/DSPE-PEG (60:45:5 
mol%) was synthesized by the ammonium sulfate gradient method as described before, with 
some modifications (108). Briefly, blank liposomes were synthesized by adding to a 10 mL 
round-bottom flask the chloroform stock solutions of DSPC (116 µL, 38 mg/mL), cholesterol 
(37 µL, 42.1 mg/mL) and DSPE-PEG-2000 (32 µL, 44.3 mg/mL). Chloroform was evaporated 
under reduced pressure at 63 ˚C for 10 minutes in a Buchi 461 water bath (BÜCHI 
Labortechnik AG, Flawil, Switzerland). Eventual residue of chloroform was withdrew by a 30 
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minutes lyophilisation in a freeze dryer ModulyoD-115-230® (Thermo Fisher Scientific 
Inc.,Waltham, MA, USA). Afterwards, the resulting lipid film was hydrated with 1 mL of 
ammonium sulfate solution 120 mM (final lipid concentration of 10 mM/mL) with 
continuous stirring (60 r.p.m, 63˚C, 1 h.). 10 cycles of freezing and thawing process (in dried 
ice and water bath at 63˚C, respectively) were applied followed by 21 cycles of extrusion in a 
mini extruder set, Avanti Polar Lipids Inc. (Al, USA) extruder charged with a 100 nm 
polycarbonate membrane. Finally, after checking the liposomes size by DLS (see 2.2.a for 
details), the liposomes suspension was diluted 1:4 (5 times) in NaCl 180 mM and dialysed in 
1 L of NaCl 180 mM for 18 hours to remove non encapsulated ammonium sulfate. For the 
synthesis of levofloxacin loaded liposomes, the dialyzed liposomes were further incubated 
with levofloxacin stock solution (40 mg/mL in acetic acid 1% v/v) with the volume ratio of 1:4 
(levofloxacin: liposome suspension) for 40 minutes under stirring in a mineral oil bath at 
63˚C. The liposomes were purified from non-encapsulated levofloxacin by 
ultracentrifugation (in a centrifuge equipped with a 10 kDa membrane) at 4000 r.f.c for 40 
min in a IEC Multi® / Multi RF TM centrifuge (Thermo Fisher Scientific Inc.,Waltham, MA, 
USA). Then, the purified liposome suspension was recovered from the filter using NaCl 180 
mM and this same solution was used to complete the final volume to 4 mL. 
 
3.4.2. Characterization of liposomes 
 
a. Liposomes size 
After production, liposomes size and size distribution (the latter expressed by the PDI – 
polydispersity index) were measured in triplicate (n=3), at 25°C by Dynamic Light Scattering 
(DLS) in the Zetasizer Nano ZS, Malvern (Malvern Instruments Ltd, Worcestershire,United 
Kingdom). Briefly, 5 µL of liposome suspension was added to 995 µL of ultra pure water. 
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b. Liposomes charge 
Liposomes charge was measured in triplicate (n=3), at 25°C in the Zetasizer Nano ZS, 
Malvern (Malvern Instruments Ltd, Worcestershire,United Kingdom). Briefly, 10 µL of 
liposomes sample was diluted to 1mL with a sodium chloride solution 4 % w/v. 
 
c. Lipid quantification 
The quantity of lipid present in the final liposomes formulations was quantified according to 
the Bartlett Assay (109). Briefly, 60 µL of sulfuric acid was added to reference glass tubes 
containing 0, 25, 50, 100 and 125 μL of phosphorus standard solution and to the sample 
tubes containing 35 µL of liposomes. The tubes were vortexed and 10 µL of hydrogen 
peroxide was added in each tube. After 10 min incubation at 200 ˚C, the tubes were cooled 
in an ice bath and 670 μL of ultra pure and 20 μL of sodium metabisulfite (0.1 g/mL) were 
added into each tube. Then, the tubes were incubated at 100 ˚C for 5 minutes and cooled in 
an ice bath. Finally, 200 μL of ammonium molybdate (0.02 g/mL) and 20 μL of ascorbic acid 
(0.1 g/mL) were added into each tube and the tubes were incubated at 100 ˚C for 10 min 
and cooled in an ice bath. Standards and samples (100 µL) were transferred to a quartz 96 
well plate and in which the absorbance of each solution was measured at 820 nm in a 
microplate Reader Safire (Tecan Group Ltd., Männedorf, Switzerland). 
 
d. Drug content inside liposomes 
Levofloxacin loaded liposome suspension was diluted in methanol (100: 900 µL) to disrupt 
lipid micelles and release the encapsulated drug. Then, 125 µL of this solution was added to 
a HPLC vial containing 875 µL of aqueous mobile phase. The levofloxacin HPLC analysis was 
performed using the same method developed to quantify levofloxacin in nanoparticles (see 
section 3.3.3). The standards of levofloxacin were prepared in the concentrations of 0; 1.25; 
2.5; 5.0; 10; 20 and 40 µg/mL. EE and LE were calculated as following: 
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EE =
quantity of encapsulated drug
total quantity of added drug
 x 100 
 
 =
quantity of encapsulated drug
(total quantity of added drug + total quantity of lipid)
 x 100 
 
 
iii. Results 
 
3.4.3. Preparation of liposomes 
Studies have shown that the encapsulation of amphipathic drugs can be increased by the 
method of ammonium sulfate gradient (108, 110) . Levofloxacin possess alkaline piperdino 
groups that display amine functionality which confers to this drug the possibility to be 
transported inside liposomes via a pH gradient formed by the ammonium sulfate. Briefly, 
amphipathic drugs in their neutral form are able to cross bilayer membrane faster than their 
neutral form. Indeed, the unprotonated levofloxacin crosses the liposomal membrane and is 
then protonated inside liposomes which is an H+ rich environment. Consequently, the 
charged drug precipitates with sulfate and forms a salt that is entrapped inside the liposome 
thus helping to increase the drug loading (111) (figure 19). 
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Figure 19: Ammonium sulfate gradient for weak bases. Liposomes are first prepared in the 
presence of ammonium sulfate (120mM). After removal of exterior ammonium sulfate by dialysis, levofloxacin (Levo) 
is added to the extraliposomal media. Ammonium sulfate can dissociate to form two ammonium cations and one sulfate annion. Ammonia 
(NH3) is free to cross the liposomal membrane giving rase to a pH gradient across the membrane. Levo in its uncharged form can cross the 
membrane and form an insoluble gel under acidic conditions with the remaining sulfate effeivelly trapping it in the liposomal interior. 
Adapted from reference (112). 
 
The lipid composition was guided by an attempt to reach a stable liposome formulation. 
DSPC was chosen since it possesses glass transition temperature (Tg) of 63˚C which results in 
higher formulation stability at room temperature and decreased drug leakage. Cholesterol 
chosen to add fluidity to the liposomes and DSPE-PEG was chosen since the hydrophilicity of 
PEG avoids aggregation of liposomes thus contributing to the stability of the lipophilic 
formulation. 
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3.4.4. Characterization of liposomes 
 
The characterization of levofloxacin loaded and blank liposomes such as size, polydispersity 
index, charge, lipid concentration and drug loading are displayed in table XVI. 
 
Table XVI: Characterization of blank and levofloxacin loaded liposomes. 
Batches Size (nm)
a,b
 PDI
a,b
 
Zeta 
Potential 
(mV)
a,b
 
Lipid 
concentration 
(mM)
c,d
 
EE (%)
a,e
 LE (%)
a,f
 
Levo Lip-1 155.7 ± 1.9 0.027 ± 0.006 -8.8± 0.3 2.065 ± 0.038 8.03 ± 0.08 7.04 ± 0.07 
Levo Lip-2 152.6 ± 2.0 0.03 ± 0.01 -8.4 ± 0.3 2.342 ± 0.003 8.7 ± 0.1 7.53 ± 0.09 
Levo Lip-3 150.6 ± 0.9 0.04 ± 0.02 -8.0 ± 0.6 2.040 ± 0.01 8.2 ± 0.2 7.1 ± 0.2 
Blank Lip-1 158.2 ± 1.7 0.02 ± 0.02 -4.6 ± 0.5 2.103 ± 0.297 - - 
Blank Lip-2 160 ± 3.5 0.03 ± 0.03 -5.3 ± 0.6 2.259 ± 0.082  - - 
Blank Lip-3 157.5 ± 2.2 0.04 ± 0.04 -5.1 ± 0.9 2.239± 0.035   
a
All values indicate mean ± SD for n=3 independent measurements for the same batch. 
b
Measured by Dynamic Light Scattering (DLS). 
c
Values calculated by the Bartlett Assay. 
d
All values indicate mean ± SD for n=2 independent measurements for the same batch. 
e
Encapsulation Efficiency (EE): (Quantity of drug encapsulated/ Total quantity of drug added) * 100. 
f
Loading Efficiency (LE): Quantity of drug encapsulated / (Total quantity of drug added + Total quantity of lipid)*100 
PDI: polydispersity index. mV: milivolts. 
 
As showed in table XVII, liposomes size was reproducible between different batches, lower 
than 200 nm and presented a monodisperse population (PDI˂ 0.2). 
 
Liposomes charge was reproducible between the batches with values of approximately -8 
mV for levofloxacin liposomes and -5 mV for blank liposomes. The slightly negative charge of 
blank liposomes can be explained by the presence DSPC with possesses negatively charged 
phosphate groups. However, the zeta potential is more negative in levofloxacin loaded 
liposomes due to the extra effect of negative ionized carboxylic groups present in 
levofloxacin.  
 
 
  
71 
 
Thus, liposomes size was suitable for particle diffusion in the mucus but the liposomes 
charge was slightly negative since neutral particles exhibit enhanced diffusion in the mucus 
(67, 77).  
 
The lipid concentration determined by the Bartlett assay presented reproducible values of 
approximately 2 mM. After all dilutions during liposomes preparation the final lipid 
concentration expected is approximately 2 mM. Thus, as can be verified in table XVI, the 
Bartlett Assay results shows that no significant loss of lipid occurred during liposomes 
preparation. 
 
The encapsulation efficiency obtained for the levofloxacin loaded liposomes was 
reproducible and around 8% w/w. Although the levofloxacin lost was considerable with the 
initial drug concentration of 40 mg/mL, the loading efficiency which expresses percentage 
w/w of drug/lipid obtained enabled to test the liposomes formulation in the microbiological 
test. According to the literature, and increased EE has been accomplished by Zhag et al in a 
study of levofloxacin encapsulation into liposomes under similar conditions. However, the 
nanoparticle size found in this study was ˃ 7 µm which may have helped to increase the LE 
(108). 
 
The results of LE showed that liposomes are better nanocarriers to encapsulate hydrophilic 
drugs such as levofloxacin compared with polymeric nanoparticles. The main reason to 
explain this fact is that the entrapment of drug inside liposomes does not depend on the 
drug- lipid interaction as happens with the use of polymers. In addition, liposomes possess 
an aqueous core which is hydrophilic and compatible with levofloxacin while PEG-g-PLA 
nanoparticles possess a hydrophobic core which does not favor polymer interaction with 
levofloxacin. Thus, as seen in the nanoparticle chapter, nanoparticles were also obtained 
with suitable size (˂ 200 nm) and slightly negafve charge. However, the best LE obtained 
was 0.02% in contrast with liposomes which exhibited LE= ~ 8%, a fact which proves that the 
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proposed liposomes formulation is a better alternative to encapsulate levofloxacin for the 
treatment of CF compared to PEG-g-PLA nanoparticles. 
 
To conclude, liposomes were successfully developed and were of consistent size, charge, 
polydispersity, lipid concentration and drug loading in three different batches of loaded 
levofloxacin and blank liposomes. Indeed, this liposomes formulations present suitable size, 
charge and drug loading to be used to target Pseudomonas aeruginosa in Cystic Fibrosis, 
thus they will be further by antimicrobial susceptibility testing. 
 
 
3.5. Assessment of free antibiotic versus antibiotic loaded nanocarriers efficiency in 
eradicating planktonic and biofilm forms of PA in antimicrobial susceptibility 
testing 
 
i. Materials 
Cation Adjusted Mueller Hinton Broth (CAMBH), Mueller Hinton Agar (MHA), Sheep blood 
defibrinated, resazurin sodium salt, Tryptic Soy Broth (TSB) and glycerol for molecular 
biology ≥ 99%, levofloxacin ˃ 98% HPLC grade were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Tissue culture plate – 96 well flat bottom with lid and 10, 200 and µL 1000 µL 
pipet tips were purchased from Sarstedt (Montreal, QC, Canada). Nunclon Delta Surface 96 
well plate was purchased from Thermo Fischer Scientific Nunc A/S (Roskilde, Denmark) and 
MBEC TM Biofilm Inoculator was purchased from Innovotech Inc. (Edmonton, AB, Canada). 
Tobramycin and Colistin Sulfate were purchased from AK Scientific (AK Scientific Inc., Union 
City, CA, USA). 
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ii. Methodology 
 
3.5.1. Validation of antimicrobial susceptibility testing with free antibiotic against 
PA 
 
3.5.1.1. Test conditions 
 
3.5.1.1.1. Bacterial strains and culture conditions 
Two different clinical strains of Pseudomonas aeruginosa (mucoid and non-mucoid) and the 
quality control strain ATCC 57853 (American Type Culture Collection, Manassas, VA), were 
kindly provided by Dr. Valerie Waters and Dr. Yvonne Yan from SickKids Hospital (Toronto, 
Canada). The clinical strains were isolated from the lungs of CF patients. After shipping, the 
strains were stored at -80°C in Tryptic Soy Broth with 15% glycerol. For antimicrobial 
susceptibility testing, the frozen strains were recovered on agar plates (Mueller Hinton agar 
with 5% v/v sheep blood) and incubated overnight at 37°C in the incubator Fisher Scientific™ 
Isotemp™ Standard Lab (Thermo Fisher Scientific Inc.,Waltham, MA, USA). After growth, 
isolates were subcultured under with similar incubation conditions. Cultures from the 
second passage were used for the testing. 
 
3.5.1.1.2. Antibiotic formulations 
The stock solution of free tobramycin, levofloxacin and colistin sulfate were prepared in ultra 
pure water at a concentration of 10 mg/mL. For the broth microdilution test in the 
planktonic form of PA, 256 µL of each stock solution was transferred to a 10 mL volumetric 
flask and the final volume completed with CAMBH to prepare the highest antibiotic 
concentration of 256 µg/mL. Serial twofold dilutions were performed to get standard 
solutions from 256 to 0.5 µg/mL. For the biofilm test, 32 µL of each stock solution (10 
mg/mL) was transferred to a 10 mL volumetric flask and the final volume completed with 
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CAMBH to prepare the highest antibiotic concentration of 32 µg/mL and the serial twofold 
dilution was similarly performed in the range of 32- 0.0625 µg/mL. 
 
3.5.2. Planktonic antimicrobial susceptibility testing against Pseudomonas 
aeruginosa 
The minimal inhibitory concentration (MIC) was determined by using a modification of the 
Clinical and Laboratory Standards Institute (CLSI) approved microtiter serial dilution method 
(113) (114). The plates were set upas indicated in figure 20: 
 SC 256 128 64 32 16 8 4 2 1 0.5 GC 
Composition of each well from column 2 to 11.                          
Example: formulation 1 = colistin sulfate 
A             (Blank): 50 µL of formulation 1 + 50 µL Broth 
B             Formulation 1: 50 µL of formulation 1 + 50 µL of inoculum 1 
C             Formulation 1: 50 µL of formulation + 50 µL of inoculum 1 
D             Formulation 1: 50 µL of formulation 1 + 50 µL of inoculum 1 
E             Formulation 1: 50 µL of formulation + 50 µL of inoculum 2 
F             Formulation 1: 50 µL of formulation + 50 µL of inoculum 2 
G             Formulation 1: 50 µL of formulation + 50 µL of inoculum 3 
H             Formulation 1: 50 µL of formulation + 50 µL of inoculum 3 
              
Figure 20: General scheme to illustrate the composition of plates for the regular 
microbiological test. SC (sterility control) = 100 µL of broth. GC (growth control) = 50 µL of broth + 50 µL of inoculum. 
Formulations (concentration range from 256 to 0.5 µg/mL): tobramycin, levofloxacin and colistin sulfate. Inoculums 1, 2 and 
3: PA mucoid strain, non-mucoid strain and quality control strain, respectively. This is a general scheme; the inoculums 
were tested in duplicate or triplicate as showed in the table XVII. 
 
As seen in the figure 20, appropriate controls (blanks), were included on each plate for the 
calculation of the bacterial counts after addition of resazurin as explained in the following 
item 1.2.3.  
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3.5.2.1. Preparation of the inoculums 
Inoculums of mucoid, non-mucoid and quality control strains of Pseudomonas aeruginosa 
were prepared in the same way. Briefly, PA suspension from overnight growth on CAMBH 
was adjusted to 0.5 McFarland turbidity standard (1 X 108 CFU/mL). This initial concentration 
was obtained by adjusting the suspension absorbance between 0.08 - 0.13 at 625 nm. Then, 
each inoculum was further diluted 1:100 (1 X 106 CFU/mL) in CAMHB to form the final 
inoculum suspension to be added in the plate. After addition of the inoculums, each 
antibiotic concentration and the inoculums their selves were diluted 1:1. Thus, the antibiotic 
range in the test was from 0.25 to 128 µg/mL and the inoculum concentration per well was 5 
X 105 CFU/ml. 
 
3.5.2.2. Inoculum checks 
After addition of the inoculum, microtiter plates were shaken briefly, and 10 µL was 
removed from 2 growth control wells (for each strain) and diluted 10:990 (10-2) in CAMBH 
followed by a consecutive dilution 100:900 (10-1) in CAMBH (total dilution of 10-3). Then, 50 
µL from last dilution was plated onto Mueller Hinton (MH) agar (it is expected 25 CFU/50 
µL), and incubated for 24 to 48 h at 37°C to confirm 5 X 10 5 CFU/mL.  
 
3.5.2.3. Incubation and addition of resazurin 
Plates were then incubated for 24 hours at 37°C without shaking. Although the optimization 
of the microbiological test was done with the free antibiotics, this test was also designed to 
determine the MIC of nanocarriers which are opaque, thus hindering the determination of 
bacterial growth by the conventional method of turbidity or optical density (OD). Therefore, 
50 µL of resazurin (0.02 % w/v) was added to each well after incubation, and the plates were 
incubated overnight at 37°C without shaking. Resazurin, a non fluorescing blue dye, is 
reduced to resorufin, a fluorescing pink dye, in the presence of actively metabolizing cells 
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(114). Therefore, MIC results were visually recorded the next day as the lowest 
concentrations of drug in which the wells remained blue. MIC results were further confirmed 
by measuring the fluorescence generated by the reduction product resorfurin on a 
Microplate Reader Safire (Tecan Group Ltd., Männedorf, Switzerland) at 560 nm 
excitation/590 nm emission. The change in metabolic activity for treated bacteria was 
calculated as follows:  
 
! =
(A − B)
(C − D)
∗ 100 
Where: 
X= change in metabolic activity (%) 
A= fluorescence of the visual MIC well 
B= fluorescence of the well with the equivalent concentration of drug without bacteria 
(blank) 
C= fluorescence of the well containing bacteria but no drug (GC) 
D= fluorescence of the well containing medium only (SC) 
The value for the MIC well should exhibit reduction ≥ 90%. 
 
3.5.3. Antimicrobial susceptibility testing of the biofilm form of Pseudomonas 
aeruginosa  
The minimal inhibitory concentration (MIC) -for the planktonic form of PA and the Minimal 
Biofilm Inhibitory Concentration (MBIC) - for the biofilm form of PA were determined in the 
Calgary Biofilm Device (115).  
 
  
77 
 
3.5.3.1. Preparation of the inoculums and biofilm formation 
Bacterial suspension of mucoid and non-mucoid strains of PA from overnight growth on 
CAMBH was adjusted to 0.5 McFarland turbidity standard (1 X 108 CFU/mL, absorbance of 
0.08 to 0.13 at 625 nm) and further diluted 300 :19700 µL in CAMHB (1 X 107 CFU/mL) and 
transferred to the Biofilm Inoculator 96 well plate as showed in figure 21. Since the biofilm 
generation time is different for each strain, the plates were set up with just one strain per 
plate. 
 1 2 3 4 5 6 7 8 9 10 11 12  
 SC           GC  
A             Blank colistin sulfate (100 µL of sterile water) – no 
biofilm growth 
B             100 µL inoculum 1 
C             100 µL inoculum 1 
D             100 µL inoculum 1 
E             Blank levofloxacin(100 µL of sterile water) – no biofilm 
growth 
F             100 µL inoculum 1 
G             100 µL inoculum 1 
H             100 µL inoculum 1 
              
Figure 21: General scheme to illustrate the composition of the biofilm inoculators 96 well 
plates for biofilm formation.SC (sterility control) = 150 µL of sterile water. Inoculums 1 or 2: PA mucoid or non-
mucoid strains (only one strain per plate). Antibiotics tested: colistin sulfate and levofloxacin. 
 
Then, the plates were incubated at 37°C with shake at 110 r.p.m for 3.5 to 4.0 hours in a 
Thermo Scientific™ MaxQ™ 4000 Benchtop Orbital Shaker (Thermo Fisher Scientific 
Inc.,Waltham, MA, USA).  
After 3.5 hours of incubation, the optical density of the wells was measured at 650 nm in the 
Microplate Reader Safire (Tecan Group Ltd., Männedorf, Switzerland) and the growth was 
stopped when the OD reached the range of 0.06 -0.07.  
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3.5.3.2. Inoculum checks 
100 µL of each inoculum (mucoid and non-mucoid) was removed in duplicate from the final 
diluted inoculums and transferred to two tubes containing 400µL of sterile water. After 
vortex, three serial dilutions 100: 900 µL in ultrapure water were performed. Finally, 50µL 
from the 2 last dilutions were plated in duplicate onto agar plates and incubated for 24 to 48 
h at 37°C to confirm 100 and 10 CFU/50 µL respectively. 
 
3.5.3.3. Biofilm incubation with antibiotic solutions (Challenge Plate) 
After growth, the peg lid containing the biofilm was removed and washed in a 96 well plate 
holding 200 µL of ultra pure water/ well to remove loosen planktonic cells and placed in the 
challenge plate containing the serial diluted antibiotic solutions, as illustrated in figure 22. 
 
Figure 22: Scheme to illustrate the biofilm rinsing in water to remove loosen planktonic cells 
and exposure to the challenge plate. Taken from reference (116). 
 
The general composition of the challenge plate is described in the figure 23. 
 
 
 
  
79 
 
 SC 32 16 8 4 2 1 0.5 0.25 0.125 0.0625 GC  
             Blank (100 µL of colistin sulfate solution) 
B             100 µL colistin solution + biofilm of strain 1 
C             100 µL colistin solution + biofilm of strain 1 
D             100 µL colistin solution + biofilm of strain 1 
E             Blank (100 µL of levofloxacin  solution)  
F             100 µL levo solution + biofilm of strain 1 
G             100 µL levo solution + biofilm of strain 1 
H             100 µL levo solution + biofilm of strain 1 
              
Figure 23: General scheme to illustrate the composition of the challenge plate SC (Sterility 
Control) and Growth Control (GC) = 150 µL of broth. Remaining wells = 150 µL of serial diluted antibiotic solution (colistin 
sulfate or levofloxacin). Biofilm: PA mucoid and non-mucoid strains (only one kind of strain per plate). Levo= levofloxacin. 
 
The challenge plates were incubated at 37°C for 24 hours without shaking.  
 
3.5.3.4. Biofilm incubation in the recovery plate 
After incubation, the peg lid was removed from the challenge antibiotic plate, washed in a 
96 well plate holding 200 µL of ultra pure water/ well to remove loosen planktonic cells and 
placed in the recovery plate containing 150 µL of CAMBH/ well as illustrated in figure 24. 
 
Figure 24: Scheme to illustrate the biofilm rinsing in water to remove loosen planktonic cells 
and exposure to the Recovery Plate. Taken from reference (116). 
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The recovery plate was incubated at 37°C for 24 hours without shaking.  
 
3.5.3.5. Addition of resazurin 
After incubation, 50 µL of resazurin (0.02 % w/v) was added to each well of the challenge 
and recovery plates which were incubated overnight at 37°C without shaking. The MIC was 
visually determined in the challenge plate as the first well which remains blue. To confirm 
the visual analysis, the spectrofluorimetric analysis was performed at 560 nm excitation/590 
nm emission in the Microplate Reader Safire (Tecan Group Ltd., Männedorf, Switzerland). 
The value for the MIC well should exhibit reduction ≥ 90%. Similarly, the Minimal Biofilm 
Inhibitory Concentration (MBIC) was determined in the recovery plate. 
 
3.5.4. Broth Microbiological Test of liposomes against Pseudomonas aeruginosa  
The Broth Microdilution test was done as described in the section 3.5.2 with some 
modifications. 
 
3.5.4.1. Antibiotics formulations 
Free levofloxacin stock solution of 256 µg/mL and two times serial dilution in CAMBH in the 
range of 256 – 0.5 µg/mL were prepared as described before. Levofloxacin loaded liposomes 
stock solution of 256 µg/mL (4 mL) was prepared considering the concentration of 
levofloxacin determined by HPLC for each liposome formulation (see table XVIII). The 
resulting lipid concentration was calculated considering the lipid quantification by the 
Bartlett Assay (see table XVIII). Similarly, blank liposomes (4 mL) were prepared using the 
same lipid total quantity as loaded liposomes of 256 µg/mL. Levofloxacin loaded liposomes 
of 256 – 0.5 µg/mL were prepared by serial dilution in broth, and similar process was applied 
for blank liposomes.  
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3.5.5. Liposomes Broth Microdilution Test in the planktonic form of Pseudomonas 
 aeruginosa 
The test was performed as described before but with the addition of free levofloxacin, blank 
and levofloxacin loaded liposomes. In addition, blanks were added in order to calculate the 
resazurin reduction with 50 µL of broth and 50 µL of each formulation. After addition of 
inoculum, the formulations were diluted 1:1 therefore the concentration of each 
formulation tested was in the range of 128 – 0.25 µg/mL. 
 
 
iii. Results and discussion 
 
3.5.6. Validation of antimicrobial susceptibility testing with free antibiotic against 
 PA. 
In order to characterize the two strains obtained from SickKids Hospital, we checked the 
susceptibility of these strains to selected drugs (tobramycin, colistin sulfate and 
levofloxacin). Thus, we determined the Minimal Inhibitory Concentration (MIC) of the 
planktonic forms of mucoid, non-mucoid and quality control Pseudomonas aeruginosa 
strains according to the standardized Broth Microdilution Test proposed by the CLSI (Clinical 
and Laboratory Standards Institute (113). 
 
Similarly, the Biofilm Minimal Inhibitory Concentration (MBIC) was assessed for the biofilm 
form of both clinical strains, according to Calgary Biofilm Device technology (115). 
The experimental conditions of both tests were therefore optimized: tobramycin activity was 
evaluated just in the planktonic form of PA while colistin sulfate and levofloxacin activities 
were evaluated in the planktonic and biofilm forms of PA. In addition, colistin sulfate was 
evaluate the biofilm form of both strains and while levofloxacin was evaluated just in the 
biofilm form of the mucoid strain. 
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The results for the preliminary microbiological tests in the planktonic and biofilm forms of 
Pseudomonas aeruginosa are presented in table XVII. 
Table XVII: Pseudomonas aeruginosa susceptibility to tobramycin, colistin sulfate and 
levofloxacin. 
Test Tobramycin Colistin sulfate Levofloxacin 
Planktonic 
(MIC) 
Mucoid = 1 μg/ml (S
b,c,g
) 
Non-mucoid = 4 μg/ml (I
b,c,g
) 
ATCC 57853 = 1 μg/ml
b,f,h
 
Mucoid = 4 μg/ml (I
a,d,g
) 
Non-mucoid = 4 μg/ml (I
a,d,h
) 
ATCC 57853 = 8 μg/ml
b,f,h
 
Mucoid = 1 μg/ml (S
a,e,g
) 
ATCC 57853 = 1 μg/mL
b,f,g
 
Biofilm 
(MIC) 
- 
Mucoid = 1 μg/ml (S
a,d,h
) 
Non-mucoid = 1 μg/ml (S
a,d,h
) 
Mucoid = 1.0 μg/ml (S
a,e,i
) 
Biofilm 
(MIBC) 
- 
Mucoid = 4 μg/ml (I
a,d,h
) 
Non-mucoid = 1 μg/ml (S
a,d,i
) 
Mucoid = 8 μg/ml (R
a,e,i
) 
a
All tests were made in triplicate for the each strain. 
b
All tests were made in duplicate. 
c
Tobramycin - Susceptible (S): MIC is ≤ 2 µg/ml; Intermediate (I): MIC = 4 µg/ml; Resistant (R): MIC ≥ 8 µg/mL. 
d
Colistin sulfate - Susceptible (S): MIC is ≤ 2 µg/ml; Intermediate (I): MIC = 4 µg/ml; Resistant (R): MIC ≥ 8 µg/mL. 
e
Levofloxacin - Susceptible (S): MIC is ≤ 2 µg/ml; Intermediate (I): MIC = 4 µg/ml; Resistant (R): MIC ≥ 8 µg/mL. 
f
ATCC 57853: Tobramycin MIC range: 0.25-1 µg/mL; Colistin: 0.5-4 µg/mL; Levofloxacin: 0.5-4 µg/mL. 
g
The test was made in three different days. 
h
The test was made in two different days. 
i
The test was made just 1 time. 
MIC: Mininal Inhibitory Concentration; MBIC: Minimal Biofilm Inhibitory Concentration.  
ATCC: American Type Cell Collection. 
 
The results showed that the planktonic form of the mucoid strain was susceptible to 
tobramycin (MIC= 1 µg/mL) while the non-mucoid strain presented intermediate 
susceptibility to tobramycin. The quality control strain presented MIC= 1 µg/mL, result 
within the expected range (0.25 – 1 µg/mL) (113) which validate the test. 
In addition, the planktonic forms of both strains had intermediate resistance to colistin 
sulfate. However, the MIC= 8 µg/mL for the quality control strain was higher than expected 
(0.5 to 4 µg/mL) (113). However, the test had inter-day (n=3) and intra-day reproducibility 
(test done in two different days) suggesting that no mistake might have occurred. Moreover, 
the same quality control strain presented expected MICs for tobramycin and levofloxacin. 
Thus, the results of MIC for colistin sulfate can be considered valid despite no obvious 
explanation for the higher MIC found in the quality control strain.  
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The susceptibility test showed that the planktonic form of the mucoid strain is susceptible to 
levofloxacin and the MIC= 1 µg/mL and the MIC for the quality control strain was within the 
expected range of 0.5-4 µg/mL (113). 
Thus, as showed in table XVII, the MIC found in the challenge plate of the Calgary biofilm 
device was in agreement with the MIC found in the regular microbiological test for 
levofloxacin. However, similar analysis for colistin sulfate presented divergent results. In fact, 
it was expected since studies carried out by Dr. Waters et al in Toronto (hospital of sickkids) 
showed that the MIC obtained from the peg panel is not comparable to the MIC obtained 
from separate MIC testing. Therefore, we will not consider the MIC provided by the biofilm 
test, just the MBIC. 
Most importantly, although the biofilm test was done on four different days, the results 
were not reproducible, suggesting that this test must be further optimized. 
It has to be noted that the Calgary biofilm characterizes MIC and MBIC in o high throughput 
way. The validation and reproducibility of this test is currently studied by Valerie Waters in 
Toronto. This is the reason why some optimization might be required to the application of 
this device. 
To conclude, this preliminary test guided our choice to select levofloxacin as drug model for 
liposomes encapsulation (see section 3.5.1) since this drug was efficient to kill the mucoid 
strain of PA. In addition, the Broth Microdilution test was selected for further evaluation of 
levofloxacin loaded liposomes activity against PA since the Calgary Biofilm Test did not 
exhibit consistent MBIC. 
 
3.5.7. Planktonic antimicrobial susceptibility testing of liposomes against 
Pseudomonas aeruginosa 
As discussed in section 3.4.4, we prepared levofloxacin loaded liposomes with appropriate 
size and charge for drug diffusion in the mucus and with suitable loading efficiency to treat 
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PA in Cystic Fibrosis (LE ~ 8% w/w). Therefore we evaluated the antibacterial efficiency of 
levofloxacin loaded liposomes as compared with blank liposomes and the free drug since we 
expect that loaded liposomes will exhibit enhanced activity against PA. 
 
The liposomes evaluation was performed by Broth Microdilution Testing and the results are 
displayed in table XVIII. 
 
Table XVIII: MIC of free levofloxacin, loaded and blank liposomes against PA 
Tests
a,b
 Formulation 
Mucoid
c
 
MIC (µg/mL) 
Non-Mucoid
c
 
MIC (µg/mL) 
Quality Control
d
 
MIC (µg/mL) 
1.1 and 1.2 (day 1) 
Free Levo-1 - 64
e,f
 1
h
 
Levo Lip-1 - 32
e,f
 - 
Blank Lip- 1 - ˃ 128
g
 - 
2.1 and 2.2 (day 2) 
Free Levo-2 1
e,f
 64
e,f
 2
g
 
Levo Lip-2 1
e,f
 32
e,f
 - 
Blank Lip- 2 ˃ 128
g
 ˃ 128
g
 - 
3.1 and 3.2 (day 3) 
Free Levo-3 1
e,f
 64
g
 2
g
 
Levo Lip-3 1
e,f
 32
g
 - 
Blank Lip- 3 ˃ 128
g
 ˃ 128
g
 - 
a Intra-day Reproducibility: two independent tests made in triplicate with the same formulation in the same day. 
bInter-day Reproducibility: 2 independent tests made in triplicate in 3 different days with new formulations in each day. 
c
Levofloxacin - Susceptible (S): MIC is ≤ 2 µg/ml; Intermediate (I): MIC = 4 µg/ml; Resistant (R): MIC ≥ 8 µg/ml. 
dQuality Control strain ATCC 57853: levofloxacin MIC range of 0.5-4 µg/mL. 
e
Result from test 1 found in duplicate (test 1 and 2 
made in the same day with the same batch). 
f
Result from test 2 found in triplicate (test 1 and 2 made in the same day with 
the same batch). 
g
Result from test 1 and test 2 found in triplicates (test 1 and 2 made in the same day with the same batch). 
h
Result from test 1 and test 2 found in duplicates (test 1 and 2 made in the same day with the same batch).MIC: Minimal 
Inhibitory Concentration. ATCC: American Type Cell Collection. Lip: liposomes. Levo: levofloxacin. 
 
As showed in table XVIII, two independent tests were done in triplicate in the same day to 
test the intra-day reproducibility and these testes were repeated in three different days with 
new liposomes and free drug formulations to check the inter-day reproducibility. 
The MIC found for the quality control strain was between 1 and 2 and this resulting range 
can be explained by small variations during the spectrophotometric analysis for the 
inoculum adjustment at 0.8 Mc Farland (OD= 0.08 – 0.13). Most importantly, the range 
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found was between the specification for the ATCC 57853 (MIC from 0.5 to 4 µg/mL) which 
validate the test and the MIC values obtained for the clinical strains. Furthermore, MIC range 
is in agreement with the results found in the preliminary tests. In addition, blank liposomes 
did not exhibit activity against PA, since the MIC found with this formulation was ˃ 128 
µg/mL. 
Although the test was done in triplicate for each strain, the MIC values obtained were either 
in duplicate or triplicate depending on the test, as can be verified in table XVIII. Indeed, for 
the mucoid strain the MIC range obtained was between 1 and 2 µg/mL for both formulations 
(free drug and loaded liposomes). Therefore, levofloxacin loaded liposomes formulation did 
not exhibit increased efficacy to eradicate the mucoid strain of Pseudomonas aeruginosa in 
vitro. Indeed, these results were expected since the mucoid strain is already very susceptible 
to the free drug. A small concentration of the free drug is enough to eradicate this strain of 
P. aeruginosa. Thus, in this case the potential benefits of the liposomes formulation could 
hardly be evaluated by the MIC, but by other tests such as the comparative mucus 
penetration of free and loaded liposomes. 
Conversely, for the non-mucoid strain the MIC range obtained for the free drug was from 64 
to 128 µg/mL while the MIC range for levofloxacin loaded liposomes was from 32 to 64 
µg/mL. Likewise, the blank liposomes formulation did not exhibit any activity against the 
non-mucoid strain. Therefore, the levofloxacin loaded liposomes formulation showed to be 2 
fold times more efficient to kill Pseudomonas aeruginosa in vitro if compared with the free 
drug. In this case the liposomes seem to present a benefit over the free drug. 
To conclude, despite the superior efficacy of the liposomes formulation to kill the non-
mucoid strain of Pseudomonas aeruginosa showed in this study, a further investigation on 
the drug release from liposomes over 48 hours should be performed to elucidate if this 
better efficacy is either due to the extended delivery of levofloxacin or to the liposomes 
uptake by the bacteria. 
These results tend to show that: 
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 Liposomes do not impair the delivery of drugs to Pseudomonas aeruginosa, since the 
antibiotic activity is similar or better than the free drug. 
 When the strain is very susceptible to the free drug (such as the mucoid strain), it is 
difficult to verify any improvement in the antibacterial effect with the use of 
liposomes. Most probably, the small levofloxacin concentration released from 
liposomes is enough to kill the bacteria. 
 When the strain is resistant to levofloxacin, liposomes might have a benefit over the 
free drug, since the MIC is reduced to a half. This superior activity might be either 
due to the extended delivery of levofloxacin or to the liposomes uptake by the 
bacteria. To confirm this result we need to study the drug release profile of the drug. 
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Chapter 4: 
 
Conclusion and Perspectives 
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The main objective of this work was to develop an antibiotic formulation to treat pulmonary 
infections in Cystic Fibrosis (CF). This is the aspect of the disease with the highest impact in 
the patient’s lifespan. Although a number of microorganisms have been isolated from the 
lungs of CF patients, the new formulation was evaluated in clinically isolated strains of 
Pseudomonas aeruginosa (mucoid and non-mucoid) kindly provided by Dr .Waters (SickKids, 
Toronto, Canada). Indeed, studies show that lung infection by Pseudomonas aeruginosa is 
related with increased morbidity and mortality of CF patients, hence the choice of this 
microorganism. 
Based on the pathological aspects of Cystic Fibrosis, the new antibiotic formulation would: 
 Circumvent the interaction of charged antibiotics with the mucus, a fact that hinders 
drug diffusion. As a consequence, sub-inhibitory antibiotic levels would favor 
bacterial resistance, biofilm formation and treatment failure. 
 Have increased efficacy against Pseudomonas aeruginosa (planktonic and biofilm 
forms) in order to avoid cyclic bacterial infections and loss of lung capacity;  
 Have the possibility to be formulated for pulmonary administration therefore 
decreasing side effects and improving the patient’s compliance to the treatment. 
In order to address these challenges we developed a polymeric PEG-g-PLA nanoparticle 
formulation since previous studies performed in our laboratory showed that: 1) PEG-g-PLA 
nanoparticles increased the efficacy of itraconazole against Candida spp.; 2) Experimental 
evidences showed that PEG-g-PLA nanoparticles might be related with decreased resistance 
in Candida strains (45); 3) PEG-g-PLA had been previously applied to encapsulate hydrophilic 
and hydrophobic drugs. Most importantly, nanoparticle with suitable size, charge, and PEG 
coating could improve particle diffusion in the mucus.  
Tobramycin loaded nanoparticles were produced by emulsification solvent evaporation (ESE) 
– double emulsion (DE) and by nanoprecipitation (NPP). Tobramycin was chosen since this 
drug is a gold standard for the treatment of CF. Optimization of production was attempted 
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to increase the efficiency of tobramycin encapsulation. Experimental results demonstrated 
that size, polydispersity and charge of tobramycin nanoparticles were reasonable for mucus 
penetration. However, drug content inside nanoparticles was low for an antibiotic 
formulation. Indeed, tobramycin concentration inside NP was lower than the limit of 
quantification allowed by spectrophotometry analysis with prior fluorescamine 
derivatization. Thus, we attempted to develop other analytic methods for tobramycin 
quantification such as HPLC (ELSD and MS detection) with polar and reverse column phase. 
However, due to its high hydrophilicity, tobramycin could not be retained in the reverse 
column. Additionally, tobramycin strongly interacted with polar columns and both 
drawbacks hindered the development of a consistent method of quantification. In fact, PEG-
g-PLA nanoparticles posses a hydrophobic core which is inappropriate for the encapsulation 
of highly hydrophilic drugs such as tobramycin. For these reasons, we decided to search for 
other drug with lower hydrophilicity aiming to reach higher loading efficiency. 
The next step consisted in evaluating the encapsulation of colistin sulfate and levofloxacin in 
PEG-g-PLA nanoparticles. However, early steps of optimization showed that levofloxacin 
exhibited higher loading efficiency than colistin sulfate. In addition, the method of 
quantification for levofloxacin exhibited lower limit of quantification, a fact that helped to 
identify small increments in loading efficiency between the batches. Therefore, we decided 
to work in further optimization for the levofloxacin nanoparticles. 
Results showed that irrespective of the method of nanoparticle preparation or drug 
composition, all nanoparticles exhibited size ˂ 200 nm, PDI ˂ 0.2 (monodisperse population) 
and charge range from -1.44 to -28.2 mV. These parameters favored mucus diffusion except 
the negative charge, since neutral particles exhibit better diffusion. 
As an attempt to increase levofloxacin encapsulation, some parameters were altered such as 
1) method of nanoparticle preparation; 2)polymer composition (addition of PLA-OH which is 
more hydrophilic than PEG-g-PLA); 3)surfactant composition; 4) solvent and co-solvent 
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composition; 5) pH; 6) drug feeding ratio and 7) additive composition. However, the best 
encapsulation efficiency reached was 0.02% w/w (formulation 10, table XV). 
The drug loading results were in accordance with the literature. In fact, it has been shown 
that polymer composition mostly impacts the drug encapsulation. Thus, the main challenge 
to develop efficacious formulation for the treatment of CF is the polymer composition. As 
most of the drugs indicated for the treatment of CF are hydrophilic, in order to favor 
drug/polymer interaction to increase drug encapsulation the polymer must be hydrophilic. 
However, the polymer must possess a balanced hydrophilicity to avoid mucus interaction.  
The second import observation is that the molecular weight may also have a significant 
impact in the drug loading. For instance, Hammady et al was able to encapsulate a high 
molecular weight hydrophilic component (calf thymus DNA) in a hydrophobic polymer (PEG-
PLA).However, altering the molecular weight without losing drug activity is a complex task.  
Therefore, we hypothesized that liposomes would be a better option to encapsulate 
hydrophilic drugs when compared to polymeric nanoparticles since the encapsulation 
process in liposomes does not depend on drug/lipid interaction.  
Levofloxacin liposomes were prepared and exhibited size, charge and polydispersity 
appropriate for mucus penetration. Moreover, the loading efficiency was as optimized to 8% 
w/w which allowed to test of this formulation in Pseudomonas aeruginosa. Most 
importantly, results showed that liposomes were twice as efficient in killing the resistant 
non-mucoid strain of Pseudomonas aeruginosa (planktonic form) as compared to the free 
drug. However, further investigation in the drug release profile should be performed to 
elucidate if its higher activity was either due to extended drug release profile of liposomes or 
to nanoparticle uptake by the bacteria. In addition, the activity of liposomes formulation in 
biofilm should also be evaluated. However, the lack of a reproducible and representative 
biofilm microbiological test restricts the progress of studies in this specific field. 
Although susceptibility tests evaluated the potential application of liposomes formulation to 
eradicate Pseudomonas aeruginosa in CF, studies to develop the final pulmonary 
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formulation must be performed since liquid liposome formulations are unstable.  As an 
alternative approach, delivery by dry powder has been considered. Examples of techniques 
applied to prepare liposomes powders are lyophilisation (to dry the liposomes) and 
micronization by jet-milling (to adjust particle size to 1-6 µm for efficient drug delivery to the 
lungs). However, both freezing and drying can lead to structural and functional changes in 
liposomes. In addition, jet-milling is also expected to induce membrane deformation 
because of high-energy collision during milling, leading to perturbation of the liposome 
structure and leakage of encapsulated drug on hydration. Likewise, after micronization the 
final formulation must be evaluated to conclude if the drug loading of liposomes provides 
therapeutic doses of antibiotic per a reasonable quantity of powder. 
The application of aptamers looks promising for the treatment of Cystic Fibrosis and is 
currently under investigation by our research group. Aptamers are an emerging class of 
nanocarriers composed of DNA or RNA strands whose composition can be optimised to favor 
the formation of a drug-aptamer conjugate. Therefore, aptamers could improve the 
encapsulation of hydrophilic drugs, such as tobramycin. As nucleotides are negatively 
charged, the conjugate drug-aptamer could be easily encapsulated into cationic liposomes. 
Thus, higher encapsulation efficiency might improve the treatment of CF and result in a final 
powder formulation with a higher concentration (suitable for pulmonary administration). In 
addition, liposomes may favor mucus penetration and aptamers may present a sustained 
release of drugs. 
As have been showed and discussed, nanotechnology is a promising and challenging field of 
study to develop innovative formulations to treat the pulmonary phase of Cystic Fibrosis. 
However, the appropriate nanocarrier should be able to provide high drug loading in order 
to be further formulated as a powder for inhalation or nebulization. Moreover, nanocarriers 
must be mucus inert to aid the diffusion of hydrophilic drugs. Nanocarriers should also 
exhibit an extended drug release and/or be able to penetrate microorganisms. In this 
research we prepared and characterized PEG-g-PLA nanoparticles versus liposomes and the 
liposome formulation seemed to be able to address these challenges. However, further 
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studies must be performed to provide the final conclusion whether liposomes are in fact a 
suitable formulation for the treatment of Cystic Fibrosis. 
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